Primary Purpose
| primary_purpose | Study_Count |
|---|---|
| Treatment | 2123 |
| Diagnostic | 61 |
| Supportive Care | 34 |
| Other | 30 |
| Prevention | 14 |
| Basic Science | 11 |
| NA | 8 |
| Health Services Research | 6 |
| Screening | 6 |
| Device Feasibility | 1 |
Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
| Type | Study_count |
|---|---|
| Total_Studies | 2620 |
| interventional | 2294 |
| Observational | 300 |
| Registry | 26 |
```
| intervention_type | Study_Count |
|---|---|
| Drug | 1309 |
| Drug|placebo | 143 |
| Drug|Radiation | 121 |
| Biological|Drug | 107 |
| Biological | 81 |
| Radiation | 76 |
| Drug|Other | 59 |
| Procedure | 49 |
| Drug|Procedure | 43 |
| Other | 35 |
| Biological|Drug|Other | 21 |
| Drug|Procedure|Radiation | 19 |
| Device | 18 |
| Behavioral | 13 |
| Biological|Drug|placebo | 13 |
| Biological|Drug|Radiation | 11 |
| Biological|Other | 11 |
| Diagnostic Test | 9 |
| Drug|Other|placebo | 9 |
| Drug|Other|Procedure | 9 |
| Drug|placebo|Radiation | 8 |
| Other|Procedure | 8 |
| Procedure|Radiation | 8 |
| Biological|placebo | 7 |
| Device|Drug | 7 |
| Drug|Other|Radiation | 7 |
| Biological|Radiation | 6 |
| Other|Radiation | 6 |
| Combination Product | 5 |
| Other|Procedure|Radiation | 5 |
| Dietary Supplement | 4 |
| Behavioral|Other|Procedure | 3 |
| Biological|Other|Radiation | 3 |
| Diagnostic Test|Drug | 3 |
| Drug|Genetic|Other | 3 |
| Drug|Other|Procedure|Radiation | 3 |
| Genetic | 3 |
| Behavioral|Drug|placebo | 2 |
| Biological|Dietary Supplement|Drug | 2 |
| Biological|Drug|Other|placebo | 2 |
| Biological|Drug|Other|Radiation | 2 |
| Biological|Other|Procedure|Radiation | 2 |
| Combination Product|Drug | 2 |
| Device|Drug|Radiation | 2 |
| Device|Other | 2 |
| Dietary Supplement|Drug | 2 |
| Drug|Genetic|Other|Procedure | 2 |
| Behavioral|Drug|Other|placebo | 1 |
| Behavioral|Drug|Other|Procedure | 1 |
| Behavioral|Radiation | 1 |
| Biological|Combination Product|Drug|Other | 1 |
| Biological|Device | 1 |
| Biological|Device|Drug|Radiation | 1 |
| Biological|Diagnostic Test | 1 |
| Biological|Drug|Genetic|Other | 1 |
| Biological|Drug|Other|Procedure | 1 |
| Biological|Drug|placebo|Radiation | 1 |
| Biological|Drug|Procedure | 1 |
| Biological|placebo|Radiation | 1 |
| Biological|Procedure | 1 |
| Combination Product|Other | 1 |
| Device|Drug|Other | 1 |
| Device|Drug|Other|Procedure | 1 |
| Device|Drug|Procedure|Radiation | 1 |
| Device|Other|Radiation | 1 |
| Device|Procedure | 1 |
| Device|Radiation | 1 |
| Diagnostic Test|Drug|Other | 1 |
| Diagnostic Test|Other|Procedure | 1 |
| Dietary Supplement|Drug|Radiation | 1 |
| Dietary Supplement|placebo | 1 |
| Drug|Genetic | 1 |
| Drug|Genetic|Other|placebo | 1 |
| Drug|Genetic|Other|Procedure|Radiation | 1 |
| Drug|Genetic|Procedure | 1 |
| Drug|Other|placebo|Procedure | 1 |
| Country | Study_Count |
|---|---|
| United States | 861 |
| China | 270 |
| NA | 83 |
| France | 75 |
| Canada | 49 |
| Japan | 41 |
| United States|Canada | 40 |
| Korea, Republic of | 38 |
| Italy | 30 |
| United Kingdom | 30 |
| Germany | 29 |
| Netherlands | 28 |
| Taiwan | 21 |
| Greece | 18 |
| Spain | 15 |
| Belgium | 14 |
| Australia | 13 |
| Denmark | 10 |
| Switzerland | 9 |
| India | 7 |
| United States|Spain | 7 |
| Israel | 6 |
| Poland | 6 |
| Singapore | 6 |
| United States|Germany | 6 |
| United States|United Kingdom | 6 |
| Norway | 5 |
| Russian Federation | 5 |
| United States|Puerto Rico | 5 |
| United States|China | 4 |
| Austria | 3 |
| Brazil | 3 |
| Sweden | 3 |
| United States|France | 3 |
| United States|India | 3 |
| United States|Korea, Republic of | 3 |
| United States|Netherlands | 3 |
| Argentina | 2 |
| China|Japan|Korea, Republic of|Taiwan | 2 |
| China|Korea, Republic of|Taiwan | 2 |
| China|Korea, Republic of|Thailand | 2 |
| Finland | 2 |
| France|Germany | 2 |
| Germany|Switzerland | 2 |
| Hong Kong | 2 |
| Hong Kong|Korea, Republic of|Singapore|Taiwan|Thailand | 2 |
| Mexico | 2 |
| Romania | 2 |
| Turkey | 2 |
| United States|Australia | 2 |
| United States|Australia|Brazil|Bulgaria|Canada|China|France|Germany|Greece|Hong Kong|Hungary|Ireland|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom | 2 |
| United States|Australia|Canada | 2 |
| United States|Australia|Japan|Korea, Republic of | 2 |
| United States|Australia|Korea, Republic of|Taiwan | 2 |
| United States|Australia|Peru|Puerto Rico | 2 |
| United States|Canada|France|Germany|Italy|Spain|United Kingdom | 2 |
| United States|Canada|Puerto Rico | 2 |
| United States|Canada|Spain|United Kingdom | 2 |
| United States|France|Hungary|Poland|Spain | 2 |
| United States|Georgia|India|Russian Federation|Ukraine | 2 |
| United States|Italy | 2 |
| United States|Japan | 2 |
| United States|Russian Federation | 2 |
| United States|Taiwan | 2 |
| NA | 1 |
| Argentina|Australia|Austria|Belgium|Brazil|China|Finland|France|Germany|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Peru|Poland|Russian Federation|Spain|Taiwan|Ukraine|United Kingdom | 1 |
| Argentina|Australia|Austria|Brazil|China|Colombia|Denmark|France|Germany|Greece|Hungary|India|Ireland|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Singapore|Spain|Sweden|Taiwan|Thailand|Turkey|United Kingdom | 1 |
| Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Czech Republic|France|Germany|Greece|Hong Kong|Hungary|Israel|Italy|Poland|Russian Federation|Spain|Taiwan|Thailand|United Kingdom | 1 |
| Argentina|Australia|Brazil|Canada|Romania|Singapore | 1 |
| Argentina|Belgium|Brazil|Bulgaria|Canada|China|Colombia|Czechia|Denmark|Germany|India|Ireland|Italy|Kazakhstan|Luxembourg|Mexico|Poland|Portugal|Romania|Slovakia|Spain|Switzerland|United Kingdom|Vietnam | 1 |
| Argentina|Brazil|Chile|Mexico | 1 |
| Argentina|Brazil|China|Colombia|Costa Rica|Denmark|Greece|Guatemala|Italy|Latvia|Lebanon|Malaysia|Mexico|Morocco|Netherlands|Panama|Peru|Philippines|Poland|Slovenia|Spain|Sweden|United Arab Emirates|United Kingdom | 1 |
| Australia|Austria|Belgium|Canada|Chile|China|Czech Republic|Denmark|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Lithuania|Malaysia|New Zealand|Poland|Romania|Russian Federation|Slovakia|Slovenia|South Africa|Spain|Ukraine|United Kingdom|Venezuela | 1 |
| Australia|Austria|Czechia|Greece|Hungary|Israel|Italy|Poland|Portugal|Russian Federation|Spain | 1 |
| Australia|Belgium|Canada|Czech Republic|Denmark|France|Germany|Hong Kong|Hungary|Italy|Netherlands|Poland|Russian Federation|Spain|Taiwan|United Kingdom | 1 |
| Australia|Belgium|China|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|Thailand | 1 |
| Australia|Belgium|China|Germany|Japan|Singapore|Spain | 1 |
| Australia|Belgium|Finland|France|Germany|Greece|India|Italy|Netherlands|Poland|Portugal|Romania|Spain|Turkey|United Kingdom | 1 |
| Australia|Belgium|France|India|Japan|Malaysia|Spain|Taiwan|Thailand | 1 |
| Australia|Belgium|France|Italy|Korea, Republic of|Lithuania|Netherlands|Poland|Romania|Singapore|Spain|Taiwan|United Kingdom | 1 |
| Australia|Belgium|Germany | 1 |
| Australia|Brazil|China|Korea, Republic of|Mexico|Taiwan | 1 |
| Australia|Brazil|Czech Republic|France|Germany|Italy|Korea, Republic of|South Africa|Taiwan|United Kingdom | 1 |
| Australia|Canada | 1 |
| Australia|Canada|Czech Republic|Netherlands|United Kingdom | 1 |
| Australia|China|Egypt|India|Korea, Republic of|Romania|Taiwan|Turkey | 1 |
| Australia|China|Hong Kong|Indonesia|Korea, Republic of|Philippines|Taiwan|Thailand | 1 |
| Australia|China|Korea, Republic of | 1 |
| Australia|Hong Kong|Korea, Republic of|Singapore | 1 |
| Australia|Italy|Mexico|Spain | 1 |
| Australia|Korea, Republic of|Malaysia | 1 |
| Australia|Netherlands|Singapore | 1 |
| Australia|New Zealand | 1 |
| Australia|New Zealand|Poland|Russian Federation|Thailand | 1 |
| Australia|New Zealand|Spain | 1 |
| Australia|Singapore | 1 |
| Australia|Taiwan | 1 |
| Australia|United Kingdom | 1 |
| Australia|United States|Austria|Belarus|Brazil|Canada|Croatia|Czechia|Denmark|Egypt|Estonia|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Latvia|Lithuania|Mexico|Netherlands|New Zealand|Norway|Poland|Portugal|Puerto Rico|Russian Federation|Serbia|Slovakia|South Africa|Spain|Sweden|Switzerland|Turkey|Ukraine|United Kingdom | 1 |
| Austria|Australia|Belgium|Canada|China|Czech Republic|Denmark|Finland|France|Germany|Greece|Hungary|Israel|Italy|Latvia|Lithuania|Netherlands|New Zealand|Philippines|Poland|Portugal|Russian Federation|Singapore|South Africa|Spain|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom | 1 |
| Austria|Belgium|Denmark|France|Germany|Netherlands|Norway|Switzerland|United Kingdom | 1 |
| Austria|Belgium|Denmark|Greece|Hungary|Ireland|Israel|Italy|Netherlands|Spain|Switzerland|United Kingdom | 1 |
| Austria|Belgium|France|Germany|Ireland|Italy|Poland|Slovenia|Spain|Switzerland|United Kingdom | 1 |
| Austria|Denmark|Finland|Greece|Hungary|Ireland|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|United Kingdom | 1 |
| Austria|Denmark|France|Germany|Italy|Spain | 1 |
| Austria|Germany|Greece|Italy|Netherlands|Spain | 1 |
| Austria|Germany|Hungary|Spain|Sweden | 1 |
| Bahamas|Canada | 1 |
| Bangladesh | 1 |
| Belarus|Bulgaria|Croatia|Georgia|Greece|Hungary|India|Latvia|Malaysia|Philippines|Poland|Russian Federation|Serbia|Slovakia|Thailand|Turkey|Ukraine | 1 |
| Belarus|Georgia|Germany|Hungary|Korea, Republic of|Poland|Romania|Russian Federation|Serbia|Spain|Taiwan|Thailand|Ukraine | 1 |
| Belarus|Hungary|Poland|Russian Federation|Ukraine | 1 |
| Belarus|India|Russian Federation|Ukraine | 1 |
| Belarus|Russian Federation | 1 |
| Belgium|Bosnia and Herzegovina|Bulgaria|Egypt|Estonia|Germany|Hungary|Italy|Lithuania|Poland|Romania|Saudi Arabia|Slovakia|Sweden|Taiwan | 1 |
| Belgium|Bulgaria|Estonia|France|Germany|Hong Kong|Ireland|Italy|Poland|Russian Federation|Singapore|Spain|Taiwan|United Kingdom | 1 |
| Belgium|Bulgaria|France|Germany|Hong Kong|Hungary|Italy|Korea, Republic of|Norway|Poland|Portugal|Russian Federation|Slovakia|Spain|Turkey | 1 |
| Belgium|China|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Portugal|Spain|Taiwan|Thailand|United Kingdom | 1 |
| Belgium|Czech Republic|Egypt|France|Germany|Greece|Italy|Netherlands|Poland|South Africa|Spain|Switzerland | 1 |
| Belgium|Czech Republic|France|Germany|Ireland|Italy|Poland|Spain | 1 |
| Belgium|Denmark|Netherlands|Sweden|United Kingdom | 1 |
| Belgium|Estonia|Finland|France|Germany|Greece|Italy|Latvia|Lithuania|Netherlands|Norway|Poland|Spain|United Kingdom| | 1 |
| Belgium|France | 1 |
| Belgium|France|Germany|Italy|Poland|Spain|United Kingdom | 1 |
| Belgium|France|Greece|Spain | 1 |
| Belgium|France|Italy|Netherlands|United Kingdom | 1 |
| Belgium|France|Spain | 1 |
| Belgium|Germany|Luxembourg | 1 |
| Belgium|Germany|Netherlands | 1 |
| Belgium|Germany|Netherlands|Spain|Switzerland | 1 |
| Belgium|Germany|Switzerland|United Kingdom | 1 |
| Belgium|Ireland|Italy|Netherlands|Spain|Switzerland | 1 |
| Belgium|Ireland|Spain | 1 |
| Belgium|Netherlands | 1 |
| Belgium|Netherlands|United Kingdom | 1 |
| Belgium|Spain | 1 |
| Belgium|Spain|United Kingdom | 1 |
| Belgium|United States|Argentina|Australia|Brazil|Canada|Chile|China|Czechia|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Japan|Jordan|Korea, Republic of|Lebanon|Netherlands|Poland|Russian Federation|Singapore|Spain|Taiwan | 1 |
| Belgium|United States|Argentina|Chile|France|Germany|Hungary|India|Italy|Netherlands|Norway|Poland|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Sweden|Switzerland|Taiwan|United Kingdom | 1 |
| Brazil|Bulgaria|Chile|Georgia|Greece|Hungary|India|Lebanon|Malaysia|Mexico|Philippines|Russian Federation|Serbia|Spain|Thailand|Turkey|Ukraine | 1 |
| Brazil|Bulgaria|China|Lithuania|Mexico|New Zealand|Poland|Russian Federation|Slovakia|Turkey | 1 |
| Brazil|Canada | 1 |
| Brazil|China|Hong Kong|India|Korea, Republic of|Taiwan|United Kingdom | 1 |
| Bulgaria | 1 |
| Bulgaria|Czech Republic|France|Romania|Ukraine | 1 |
| Bulgaria|France|Greece|Hungary|Italy|Norway|Poland|Portugal|Romania|Spain|Switzerland|Turkey|United Kingdom | 1 |
| Canada|Germany|Hong Kong|Italy|Singapore|Taiwan | 1 |
| Canada|Hungary|Poland|Romania | 1 |
| Canada|Italy | 1 |
| Canada|Korea, Republic of|Taiwan | 1 |
| Canada|United States|Brazil|Germany|Korea, Republic of|Poland|Romania|Russian Federation|United Kingdom | 1 |
| Canada|United States|Japan|Romania|South Africa | 1 |
| Chile|China|Croatia|Egypt|India|Malaysia|Malta|Morocco|Pakistan|Panama|Peru|South Africa|Tunisia | 1 |
| Chile|France|Italy|Korea, Republic of|Latvia|New Zealand|Poland|Spain|United Kingdom | 1 |
| China|Austria|Belarus|Belgium|Bulgaria|Croatia|Czechia|Denmark|France|Georgia|Germany|Greece|India|Israel|Italy|Korea, Republic of|Lithuania|Poland|Portugal|Romania|Russian Federation|Slovakia|South Africa|Spain|Switzerland|Ukraine|United Kingdom | 1 |
| China|Denmark|Egypt|France|Germany|Netherlands|Spain|Switzerland|Turkey | 1 |
| China|France|Germany|Hong Kong|Hungary|Italy|Japan|Korea, Republic of|Russian Federation|Spain|Taiwan | 1 |
| China|Hong Kong|India|Philippines|Taiwan|Thailand|Vietnam | 1 |
| China|Hong Kong|India|Singapore|Taiwan | 1 |
| China|Hong Kong|Indonesia|Japan|Malaysia|Philippines|Singapore|Taiwan|Thailand | 1 |
| China|Hong Kong|Indonesia|Korea, Republic of|Philippines|Taiwan|Thailand | 1 |
| China|Hong Kong|Malaysia|Taiwan|Thailand | 1 |
| China|Hong Kong|Russian Federation|Singapore | 1 |
| China|Italy|Korea, Republic of|Malaysia|Singapore|Spain|Taiwan | 1 |
| China|Korea, Republic of | 1 |
| China|Korea, Republic of|Malaysia|Singapore|Thailand | 1 |
| China|Malaysia | 1 |
| China|Malaysia|Philippines | 1 |
| China|Thailand | 1 |
| China|United States|Australia|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Malaysia|Philippines|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom|Vietnam | 1 |
| China|United States|Australia|Belgium|Brazil|Canada|France|Germany|Hong Kong|Hungary|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden|Taiwan|Thailand|Turkey|Ukraine|Vietnam | 1 |
| China|United States|Australia|Canada|France|Germany|Hong Kong|Hungary|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Russian Federation|Spain|Sweden|Taiwan|United Kingdom | 1 |
| Cyprus | 1 |
| Czech Republic|Germany|Netherlands | 1 |
| Czech Republic|United States|Australia|Bulgaria|Canada|France|Germany|Greece|Hungary|India|Italy|Korea, Republic of|Latvia|Malaysia|Philippines|Poland|Romania|Russian Federation|Singapore|Spain|Taiwan|Turkey|United Kingdom | 1 |
| Denmark|France|Germany|Italy|Korea, Republic of|Netherlands|Spain|Taiwan|United Kingdom | 1 |
| Denmark|Germany|Italy|Spain|Sweden | 1 |
| Denmark|United Kingdom | 1 |
| Egypt | 1 |
| Egypt|Estonia|Argentina|Australia|Austria|Bosnia and Herzegovina|Brazil|Canada|China|Colombia|Czech Republic|Denmark|Ecuador|Finland|France|Germany|Hong Kong|Hungary|Iceland|Israel|Italy|Latvia|Lebanon|Lithuania|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|Slovenia|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom|Venezuela | 1 |
| Egypt|Lebanon|Saudi Arabia | 1 |
| Egypt|Malaysia|Philippines|Poland|Romania|Serbia|Thailand | 1 |
| Finland|Germany|Italy|Netherlands|United Kingdom | 1 |
| France|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Chile|Czech Republic|Germany|Hong Kong|Hungary|Ireland|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Russian Federation|Singapore|Slovakia|Spain|Sweden|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| France|Czechia|Germany|Greece|Italy|Poland|Romania|Spain | 1 |
| France|Germany|Greece|Italy|Korea, Republic of|Netherlands|Russian Federation|Spain|Sweden|Switzerland|Turkey|United Arab Emirates | 1 |
| France|Germany|Hungary|Poland | 1 |
| France|Germany|Italy|Netherlands|Spain|United Kingdom | 1 |
| France|Germany|Italy|Spain | 1 |
| France|Germany|Italy|Spain|United Kingdom | 1 |
| France|Germany|Spain | 1 |
| France|Italy|Spain | 1 |
| France|Jordan|Poland|Slovenia|Spain | 1 |
| France|Korea, Republic of|Spain | 1 |
| France|Korea, Republic of|Spain|United Kingdom | 1 |
| France|Switzerland|United Kingdom | 1 |
| France|United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czechia|Germany|Ireland|Italy|Japan|Mexico|Netherlands|Poland|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|United Kingdom | 1 |
| France|United States|Spain|United Kingdom | 1 |
| Georgia | 1 |
| Germany|Italy | 1 |
| Germany|Italy|Netherlands|Poland|United Kingdom | 1 |
| Germany|Italy|Poland|United Kingdom | 1 |
| Germany|Netherlands|Spain|Switzerland | 1 |
| Germany|Poland | 1 |
| Germany|Spain | 1 |
| Germany|United Kingdom | 1 |
| Germany|United States|Argentina|Belgium|Brazil|Canada|China|Croatia|Denmark|Estonia|France|Hong Kong|Indonesia|Italy|Latvia|Malaysia|Mexico|Philippines|Singapore|Slovenia|Spain|Sweden|Switzerland|Thailand|Turkey | 1 |
| Germany|United States|Argentina|France|Israel|Italy|Latvia|Spain|United Kingdom | 1 |
| Germany|United States|Austria | 1 |
| Germany|United States|Canada | 1 |
| Greece|Australia|Belarus|Brazil|Bulgaria|Chile|China|Colombia|Czechia|Georgia|Hungary|Jordan|Lebanon|Malaysia|Mexico|Philippines|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|Turkey|Ukraine | 1 |
| Greece|Germany|Australia|Austria|Belgium|Canada|Czech Republic|Estonia|Finland|France|Hong Kong|Hungary|Italy|Poland|Spain | 1 |
| Hong Kong|India|China|Korea, Republic of|Mexico|Philippines|Poland|Russian Federation|Taiwan|Turkey | 1 |
| Hong Kong|Korea, Republic of|Malaysia|Philippines|Singapore|Taiwan|Thailand | 1 |
| Hong Kong|Korea, Republic of|Malaysia|Singapore|Taiwan|Thailand | 1 |
| Hong Kong|Korea, Republic of|Taiwan|Thailand | 1 |
| Hungary|Poland|Russian Federation | 1 |
| Hungary|Serbia|Spain | 1 |
| Hungary|United States|Austria|France|Italy|Poland|Romania|Spain | 1 |
| Hungary|United States|Belgium|Czechia|Italy|Korea, Republic of|United Kingdom | 1 |
| Ireland | 1 |
| Ireland|Korea, Republic of|Netherlands|Singapore|Spain|Switzerland | 1 |
| Ireland|United Kingdom | 1 |
| Israel|Italy|Japan|United States|Belgium|Canada|China|France|Germany|Korea, Republic of|Netherlands|Poland|Spain|United Kingdom | 1 |
| Italy|Netherlands|Poland|South Africa|United Kingdom | 1 |
| Italy|Netherlands|Spain|United Kingdom | 1 |
| Italy|United States|Argentina|Australia|Austria|Canada|Chile|Czechia|France|Germany|Hungary|Ireland|Mexico|Netherlands|Peru|Poland|Romania|Russian Federation|Spain|United Kingdom | 1 |
| Italy|United States|France|Germany|India|Poland|Russian Federation|Ukraine | 1 |
| Japan|Brazil|Czechia|Hungary|India|Korea, Republic of|Mexico|Peru|Philippines|Poland|Russian Federation|Thailand|Turkey|Vietnam | 1 |
| Japan|Korea, Republic of|Singapore|Taiwan | 1 |
| Japan|Korea, Republic of|Taiwan | 1 |
| Japan|United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|China|France|Germany|Ireland|Italy|Mexico|Poland|Romania|Russian Federation|Spain|United Kingdom | 1 |
| Japan|United States|Argentina|Brazil|China|Hungary|India|Korea, Republic of|Malaysia|Peru|Russian Federation|Spain|Taiwan|Thailand|Turkey|Vietnam | 1 |
| Jordan|Lebanon | 1 |
| Kazakhstan|Russian Federation | 1 |
| Korea, Republic of|Poland | 1 |
| Mexico|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Czechia|Denmark|France|Germany|Hungary|Italy|Netherlands|Peru|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom | 1 |
| Netherlands|Spain|Switzerland | 1 |
| Netherlands|United Kingdom | 1 |
| Peru|United States|Argentina|Australia|Brazil|Canada|Italy|Korea, Republic of|New Zealand|Philippines|Taiwan|Thailand | 1 |
| Poland|Albania|Argentina|Australia|Austria|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Chile|China|Colombia|Croatia|Czech Republic|Ecuador|Egypt|Estonia|Finland|Germany|Greece|Guatemala|Hong Kong|Hungary|India|Indonesia|Ireland|Israel|Italy|Korea, Republic of|Latvia|Lithuania|Malaysia|Mexico|Netherlands|New Zealand|Panama|Peru|Portugal|Romania|Russian Federation|Saudi Arabia|Serbia|Slovakia|Slovenia|Sweden|Switzerland|Taiwan|Thailand|Turkey|Uruguay|Venezuela | 1 |
| Poland|Romania|South Africa|Ukraine | 1 |
| Poland|Russian Federation|United States|Australia|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Singapore|Spain|Taiwan|United Kingdom | 1 |
| Poland|Spain|China|Hong Kong|Italy|Japan|Korea, Republic of | 1 |
| Poland|Spain|United States|France|Italy|Japan | 1 |
| Poland|United States|Belarus|Bosnia and Herzegovina|Bulgaria|Croatia|Georgia|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Peru|Philippines|Romania|Russian Federation|Serbia|Spain|Taiwan|Thailand|Turkey|Ukraine|Vietnam | 1 |
| Portugal | 1 |
| Romania|Australia|Austria|Belgium|Canada|Chile|China|Czech Republic|Denmark|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Lithuania|Malaysia|Netherlands|New Zealand|Poland|Russian Federation|Slovakia|Slovenia|South Africa|Spain|Ukraine|United Kingdom|Venezuela | 1 |
| Russian Federation|Taiwan|United States|Austria|Belgium|Korea, Republic of|Poland|Thailand | 1 |
| Russian Federation|Ukraine | 1 |
| Serbia | 1 |
| Slovakia|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|France|Germany|Israel|Italy|Japan|Latvia|Lithuania|Mexico|Netherlands|Peru|Portugal|Russian Federation|Singapore|Spain|Taiwan|Ukraine | 1 |
| Spain|Austria|Belgium|Brazil|Canada|China|Cyprus|Finland|France|Germany|Greece|Hungary|Israel|Italy|Mexico|Netherlands|Switzerland|United Kingdom | 1 |
| Spain|Taiwan|United States|Argentina|France|Germany|Israel|Italy|Latvia|Malaysia|Mexico|Philippines|United Kingdom | 1 |
| Spain|United States|Argentina|Australia|Austria|Brazil|Canada|Chile|China|Colombia|Czechia|Denmark|Finland|France|Germany|Greece|Hong Kong|Hungary|Iceland|India|Italy|Japan|Korea, Republic of|Lebanon|Malaysia|Netherlands|Norway|Philippines|Poland|Portugal|Romania|Russian Federation|Singapore|Slovakia|South Africa|Sweden|Switzerland|Taiwan|Thailand|Turkey|United Kingdom|Vietnam | 1 |
| Spain|United States|Canada|Germany|Korea, Republic of|Taiwan | 1 |
| Sweden|United Kingdom | 1 |
| Turkey|United States|Australia|Belgium|Brazil|Canada|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Russian Federation|Singapore|Spain|Taiwan|United Kingdom | 1 |
| Ukraine|United Kingdom|United States|Belgium|Hungary|India|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Russian Federation | 1 |
| Ukraine|United States|Belarus|Belgium|Canada|Czechia|France|Germany|Hungary|Italy|Netherlands|Poland|Russian Federation|Serbia|Slovenia|Spain | 1 |
| United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|France|Germany|Hungary|Israel|Italy|Mexico|Netherlands|Peru|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|France|Germany|Italy|Japan|Latvia|Lithuania|Mexico|Netherlands|Peru|Portugal|Russian Federation|Singapore|Slovakia|Spain|Switzerland|Taiwan|Ukraine | 1 |
| United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|China|Colombia|Czechia|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Netherlands|Peru|Poland|Romania|Russian Federation|Saudi Arabia|South Africa|Spain|Switzerland|Taiwan|Turkey|United Arab Emirates|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|France|Germany|Hong Kong|Hungary|Ireland|Italy|Japan|Korea, Republic of|Malaysia|Peru|Philippines|Romania|Russian Federation|Taiwan|Thailand|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czechia|Finland|France|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Romania|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Finland|France|Germany|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Puerto Rico|Spain|Sweden|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Belgium|Brazil|Chile|Colombia|Czech Republic|Egypt|Former Yugoslavia|France|Greece|Israel|Italy|Japan|Lithuania|Macedonia, The Former Yugoslav Republic of|Morocco|Norway|Philippines|Poland|Portugal|Slovenia|South Africa|Spain|Sweden|Switzerland|Tunisia | 1 |
| United States|Argentina|Australia|Austria|Belgium|Bulgaria|Chile|China|France|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Malaysia|Netherlands|Peru|Portugal|Romania|Russian Federation|Spain|Taiwan|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Belgium|Canada|China|France|Germany|Hong Kong|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Peru|Philippines|Singapore|Spain|Taiwan|Thailand|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Belgium|Canada|Czech Republic|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Spain|Taiwan|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Chile|China|Czech Republic|Estonia|Finland|France|Germany|Greece|Hong Kong|Hungary|India|Italy|Korea, Republic of|Malaysia|Netherlands|Poland|Portugal|Romania|Russian Federation|Singapore|Spain|Sweden|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Brazil|Canada|Chile|Czechia|France|Germany|Hong Kong|Hungary|Italy|Mexico|Norway|Peru|Poland|Romania|Russian Federation|Singapore|Spain|Switzerland | 1 |
| United States|Argentina|Australia|Austria|Brazil|Canada|Colombia|France|Germany|Japan|Korea, Republic of|New Zealand|Poland|Romania|Russian Federation|Spain|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Brazil|Canada|France|Germany|Hungary|Italy|Japan|Korea, Republic of|New Zealand|Norway|Poland|Russian Federation|Spain|Switzerland|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Brazil|Denmark|France|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Peru|Poland|Russian Federation|Serbia|Spain|Switzerland|Taiwan|Thailand|Turkey|Ukraine | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Chile|Colombia|Croatia|Czechia|Denmark|France|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Peru|Poland|Romania|Russian Federation|Slovakia|South Africa|Spain|Switzerland|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Hong Kong|Israel|Italy|Mexico|Philippines|Romania|Singapore|Spain|Taiwan|Thailand|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|Costa Rica|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Panama|Peru|Poland|Russian Federation|Serbia|Singapore|Spain|Taiwan|Thailand|Turkey | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|Croatia|France|Germany|Hong Kong|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Peru|Poland|Russian Federation|Serbia|South Africa|Spain|Taiwan|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|France|Germany|Greece|Ireland|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Puerto Rico|Romania|Spain|Sweden|Switzerland|Taiwan|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Romania|Russian Federation|Singapore|Spain|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Hong Kong|Israel|Italy|Korea, Republic of|Netherlands|Peru|Poland|Russian Federation|Spain|Turkey|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|China|France|Germany|Greece|India|Ireland|Korea, Republic of|Netherlands|Portugal|Spain|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|Colombia|France|Germany|Hong Kong|Korea, Republic of|Mexico|Philippines|Singapore|Spain|Taiwan|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Brazil|Canada|Czechia|Japan|Korea, Republic of|Netherlands|Spain|Taiwan | 1 |
| United States|Argentina|Australia|Belgium|Bulgaria|Canada|Chile|China|France|Hungary|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Turkey | 1 |
| United States|Argentina|Australia|Belgium|Canada|China|Czechia|France|Germany|Hong Kong|India|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Russian Federation|Singapore|Spain|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Australia|Belgium|Colombia|France|Germany|Greece|Hong Kong|India|Israel|Italy|Mexico|Philippines|Portugal|South Africa|Spain|Sweden|Taiwan|United Kingdom|Venezuela | 1 |
| United States|Argentina|Australia|Bosnia and Herzegovina|Brazil|Canada|Chile|Colombia|Ecuador|Germany|Hong Kong|Hungary|Ireland|Korea, Republic of|Latvia|Macedonia, The Former Yugoslav Republic of|Malaysia|Mexico|Moldova, Republic of|Netherlands|New Zealand|Panama|Peru|Philippines|Poland|Romania|Serbia|Sweden|Taiwan|Thailand|Turkey|Ukraine | 1 |
| United States|Argentina|Australia|Brazil|Canada|Chile|China|Germany|Greece|Israel|Mexico|New Zealand|Romania|Singapore|South Africa|Sweden|Thailand | 1 |
| United States|Argentina|Australia|Brazil|Canada|Chile|Colombia|France|Germany|Hungary|Ireland|Italy|Korea, Republic of|Latvia|Mexico|Peru|Poland|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Brazil|Canada|Chile|France|Germany|Hungary|Israel|Italy|Netherlands|Russian Federation|Spain|Ukraine|United Kingdom | 1 |
| United States|Argentina|Australia|Brazil|Canada|China|Czechia|India|Japan|Korea, Republic of|Peru|Philippines|Russian Federation|Slovakia|South Africa|Taiwan|Thailand|United Kingdom|Vietnam | 1 |
| United States|Argentina|Australia|Brazil|Canada|China|Denmark|France|Germany|Hong Kong|India|Indonesia|Italy|Korea, Republic of|Mexico|Netherlands|Norway|Philippines|Spain|Taiwan|Thailand|United Kingdom | 1 |
| United States|Argentina|Australia|Brazil|Chile|India | 1 |
| United States|Argentina|Australia|Canada|Czechia|Denmark|Finland|Germany|Hungary|Israel|Japan|Korea, Republic of|Netherlands|New Zealand|Russian Federation|South Africa|Spain|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Australia|France|Germany|Italy|Korea, Republic of|Russian Federation|Spain|Taiwan | 1 |
| United States|Argentina|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|China|France|Germany|Greece|Hong Kong|Hungary|India|Indonesia|Israel|Italy|Japan|Korea, Republic of|Netherlands|Pakistan|Peru|Philippines|Poland|Russian Federation|Singapore|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|United Kingdom | 1 |
| United States|Argentina|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|China|France|Germany|Hungary|India|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Peru|Philippines|Romania|Russian Federation|Spain|Taiwan|Thailand|Vietnam | 1 |
| United States|Argentina|Austria|Belgium|Brazil|Canada|China|Denmark|France|Germany|Greece|India|Indonesia|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Portugal|Singapore|Spain|Thailand|Turkey|Vietnam | 1 |
| United States|Argentina|Austria|Belgium|Brazil|Canada|France|Germany|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|Netherlands|Norway|Poland|Russian Federation|Singapore|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Austria|Belgium|Brazil|Denmark|France|Germany|Greece|Italy|Japan|Lebanon|Mexico|Netherlands|Oman|Slovakia|Spain|United Arab Emirates | 1 |
| United States|Argentina|Austria|Brazil|Bulgaria|Canada|Chile|China|Colombia|Czechia|France|Germany|Greece|Guatemala|Hong Kong|Hungary|Iceland|India|Israel|Italy|Japan|Jordan|Korea, Republic of|Lebanon|Malaysia|Mexico|Norway|Panama|Peru|Philippines|Poland|Portugal|Romania|Russian Federation|South Africa|Spain|Switzerland|Taiwan|Thailand|Turkey|United Kingdom|Vietnam | 1 |
| United States|Argentina|Austria|Brazil|Canada|Chile|Finland|France|Germany|Greece|Guatemala|Hungary|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Norway|Panama|Poland|Portugal|Russian Federation|Serbia|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Austria|Brazil|Canada|France|Germany|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|Netherlands|New Zealand|Norway|Poland|Puerto Rico|Romania|Russian Federation|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Austria|Canada|Chile|China|Croatia|France|Germany|Greece|Hong Kong|Italy|Korea, Republic of|Mexico|Romania|Russian Federation|Spain|Sweden|Taiwan|Thailand | 1 |
| United States|Argentina|Austria|Canada|Chile|China|Denmark|France|Germany|Greece|Hungary|India|Ireland|Italy|Korea, Republic of|Mexico|Netherlands|Portugal|Singapore|Spain|Taiwan|Turkey|United Kingdom | 1 |
| United States|Argentina|Belgium|Brazil|Canada|China|France|Germany|Greece|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Spain|Taiwan|Turkey|Ukraine | 1 |
| United States|Argentina|Belgium|Brazil|Canada|China|France|Germany|Ireland|Italy|Japan|Korea, Republic of|Poland|Romania|Russian Federation|South Africa|Spain|Taiwan|Ukraine|United Kingdom | 1 |
| United States|Argentina|Belgium|Brazil|Canada|France|Germany|Hong Kong|Hungary|Italy|Japan|Netherlands|Singapore|Spain|Taiwan|Thailand|Turkey|United Kingdom | 1 |
| United States|Argentina|Belgium|Brazil|Canada|France|Germany|Israel|Italy|Netherlands|Spain|Turkey | 1 |
| United States|Argentina|Belgium|Germany|South Africa|United Kingdom | 1 |
| United States|Argentina|Brazil|Bulgaria|Chile|China|Denmark|Finland|Greece|Hong Kong|India|Israel|Japan|Korea, Republic of|Malaysia|Mexico|Peru|Philippines|Poland|Portugal|Qatar|Romania|Russian Federation|Saudi Arabia|Singapore|Sweden|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Brazil|Bulgaria|Chile|Colombia|Greece|Hungary|Mexico|Peru|Poland|Romania|Russian Federation|Spain|Turkey|Ukraine | 1 |
| United States|Argentina|Brazil|Bulgaria|Chile|Croatia|Egypt|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Philippines|Poland|Portugal|Romania|Russian Federation|Serbia|South Africa|Spain|Thailand|Turkey|Ukraine|United Kingdom|Vietnam | 1 |
| United States|Argentina|Brazil|Canada|China|France|Greece|Hungary|Italy|Japan|Korea, Republic of|Romania|Spain|Taiwan|Turkey | 1 |
| United States|Argentina|Brazil|Czech Republic|Hungary|India | 1 |
| United States|Argentina|Canada|France|Korea, Republic of|Poland|Spain|Taiwan | 1 |
| United States|Argentina|China|Korea, Republic of | 1 |
| United States|Argentina|France|Hungary|Spain|Thailand | 1 |
| United States|Australia|Austria|Belarus|Bosnia and Herzegovina|China|Denmark|Egypt|France|Germany|Greece|Hungary|Israel|Italy|Japan|Kazakhstan|Korea, Republic of|Latvia|Lebanon|North Macedonia|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Singapore|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Colombia|Czechia|Germany|Greece|India|Italy|Korea, Republic of|Lebanon|Malaysia|Netherlands|Poland|Russian Federation|Spain|Taiwan|Thailand|Turkey|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Brazil|Canada|Croatia|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Philippines|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Brazil|Canada|Croatia|France|Germany|Greece|Hungary|Italy|Poland|Portugal|Romania|Russian Federation|Slovakia|South Africa|Spain|United Kingdom | 1 |
| United States|Australia|Austria|Belgium|Canada|France|Germany|Netherlands | 1 |
| United States|Australia|Austria|Belgium|Canada|France|Israel|Italy|Spain | 1 |
| United States|Australia|Austria|Brazil|Bulgaria|China|Croatia|Czech Republic|Germany|Greece|Hungary|India|Italy|Korea, Republic of|Netherlands|Poland|Romania|Spain|Taiwan|Turkey | 1 |
| United States|Australia|Austria|Brazil|China|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Poland|Russian Federation|Serbia|Slovenia|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Austria|Canada|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Spain|Sweden|Taiwan | 1 |
| United States|Australia|Austria|Canada|Denmark|France|Germany|Hong Kong|Italy|Korea, Republic of|Luxembourg|Netherlands|Norway|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom | 1 |
| United States|Australia|Austria|Canada|France|Italy|Spain|Switzerland | 1 |
| United States|Australia|Belarus|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Poland|Russian Federation|Serbia|Slovenia|Spain|Ukraine | 1 |
| United States|Australia|Belgium|Bosnia and Herzegovina|Bulgaria|Canada|France|Georgia|Germany|Hong Kong|Italy|Japan|Netherlands|Singapore|Slovenia|Spain|Switzerland|Turkey|United Kingdom | 1 |
| United States|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|China|Colombia|Croatia|Cyprus|Czechia|Denmark|Estonia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Lebanon|Lithuania|Netherlands|New Zealand|Peru|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Chile|France|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Peru|Poland|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom|Vietnam | 1 |
| United States|Australia|Belgium|Canada|China|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|Turkey|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Singapore|Spain|Switzerland|Taiwan | 1 |
| United States|Australia|Belgium|Canada|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Netherlands|Russian Federation|Spain|Switzerland|Taiwan|Thailand|Vietnam | 1 |
| United States|Australia|Belgium|Canada|France|Germany|Ireland|Italy|Poland|Spain|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|France|Hong Kong|Italy|Japan|Korea, Republic of|New Zealand|Norway|Russian Federation|Singapore|Spain|Sweden|Taiwan|Thailand|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Germany|Spain | 1 |
| United States|Australia|Belgium|Canada|Greece|Spain | 1 |
| United States|Australia|Belgium|Canada|Hong Kong|Italy|Netherlands|Singapore|Spain | 1 |
| United States|Australia|Belgium|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|Belgium|Croatia|Poland|Romania|Russian Federation | 1 |
| United States|Australia|Belgium|Denmark|France|Germany|Italy|Korea, Republic of|Luxembourg|Netherlands|Russian Federation|Singapore|Spain|Sweden|Taiwan|United Kingdom | 1 |
| United States|Australia|Belgium|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Romania|Russian Federation|Spain|Taiwan|Ukraine | 1 |
| United States|Australia|Belgium|France|Germany|Italy|Korea, Republic of|Poland|Spain|Sweden | 1 |
| United States|Australia|Belgium|France|Italy|Korea, Republic of|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|Belgium|Greece|Japan|Korea, Republic of|Netherlands | 1 |
| United States|Australia|Bosnia and Herzegovina|Brazil|Canada|Chile|China|Costa Rica|Egypt|France|Germany|Guatemala|Hong Kong|Israel|Italy|Korea, Republic of|Mexico|New Zealand|Poland|Portugal|Russian Federation|Serbia|Singapore|Spain|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Brazil|Bulgaria|Chile|Croatia|Czechia|France|Germany|Greece|Hungary|India|Italy|Japan|Korea, Republic of|Malaysia|Netherlands|Philippines|Poland|Romania|Russian Federation|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine | 1 |
| United States|Australia|Brazil|Canada|China|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Mexico|Spain|Sweden|Taiwan|United Kingdom | 1 |
| United States|Australia|Brazil|Canada|Hong Kong|Korea, Republic of|Poland|Puerto Rico|Singapore|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|Brazil|Czech Republic|Russian Federation|Singapore | 1 |
| United States|Australia|Brazil|France|Bulgaria|Canada|China|Hungary|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Poland|Romania|Singapore|Spain|Taiwan|Ukraine | 1 |
| United States|Australia|Bulgaria | 1 |
| United States|Australia|Canada|China|Colombia|Estonia|France|Hungary|Israel|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Poland|Russian Federation|Taiwan|Turkey|Ukraine | 1 |
| United States|Australia|Canada|China|France|Italy|Japan|Korea, Republic of|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|Canada|Colombia|France|Hungary|Israel|Italy|Japan|Korea, Republic of|Puerto Rico|Russian Federation|Spain|United Kingdom | 1 |
| United States|Australia|Canada|Czech Republic|France|Greece|Hungary|Israel|Poland|Russian Federation|United Kingdom | 1 |
| United States|Australia|Canada|Czechia|France|Germany|Greece|Italy|Netherlands|United Kingdom | 1 |
| United States|Australia|Canada|Czechia|Hungary|Italy|Spain|United Kingdom | 1 |
| United States|Australia|Canada|Denmark|Estonia|Ireland|Israel|Italy|Japan|Korea, Republic of|Malaysia|Poland|Russian Federation|Spain|Switzerland|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Canada|Denmark|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Singapore|Spain|Switzerland|Taiwan|United Kingdom | 1 |
| United States|Australia|Canada|Finland|France|Germany|Italy|Norway|Poland|Spain|Sweden | 1 |
| United States|Australia|Canada|France|Germany|Italy|Korea, Republic of|Norway|Singapore|Spain|Taiwan | 1 |
| United States|Australia|Canada|Hong Kong|Ireland|Italy|Japan|Korea, Republic of|Poland|Russian Federation|Singapore|South Africa|Spain|Switzerland|Taiwan|United Kingdom | 1 |
| United States|Australia|Canada|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Russian Federation|Spain|Taiwan|Turkey|United Kingdom | 1 |
| United States|Australia|Canada|Hungary|Italy|Korea, Republic of|Poland|Taiwan|United Kingdom | 1 |
| United States|Australia|Canada|Israel|Korea, Republic of | 1 |
| United States|Australia|Chile|Croatia|France|Germany|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Serbia|Ukraine | 1 |
| United States|Australia|China | 1 |
| United States|Australia|China|Hungary|Korea, Republic of|Netherlands|Poland|Russian Federation|Taiwan|Thailand|Turkey|Vietnam | 1 |
| United States|Australia|Czech Republic|France|Germany|Hungary|Poland | 1 |
| United States|Australia|France|Germany|Hungary|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Spain|Taiwan|Ukraine | 1 |
| United States|Australia|France|Germany|Italy|Japan|Korea, Republic of|Spain|Taiwan|United Kingdom | 1 |
| United States|Australia|France|Germany|Italy|Netherlands|Singapore|Spain|Switzerland | 1 |
| United States|Australia|France|Germany|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|United Kingdom | 1 |
| United States|Australia|France|Germany|Korea, Republic of|Spain|Taiwan | 1 |
| United States|Australia|France|Israel|Korea, Republic of|Spain|United Kingdom | 1 |
| United States|Australia|France|Italy|Japan | 1 |
| United States|Australia|Germany | 1 |
| United States|Australia|Germany|Italy|United Kingdom | 1 |
| United States|Australia|Hong Kong|Korea, Republic of|Singapore|Taiwan | 1 |
| United States|Australia|Hungary|Israel|Poland|Russian Federation|United Kingdom | 1 |
| United States|Australia|Italy|Singapore|Spain | 1 |
| United States|Australia|Japan|Korea, Republic of|Spain | 1 |
| United States|Australia|New Zealand|Poland|Thailand | 1 |
| United States|Australia|Puerto Rico|South Africa | 1 |
| United States|Australia|Spain|United Kingdom | 1 |
| United States|Austria|Belgium|Bulgaria|Germany|Hungary|Israel|Italy|Lithuania|Romania|Slovenia|Ukraine|United Kingdom | 1 |
| United States|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Italy|Japan|Korea, Republic of|Philippines|Poland|Singapore|Spain|Taiwan|Thailand|United Kingdom | 1 |
| United States|Austria|Belgium|Canada|Czechia|France|Germany|Italy|Netherlands|Poland|Spain|Switzerland | 1 |
| United States|Austria|Belgium|Canada|Finland|France|Germany|Italy|Netherlands|Poland|Portugal|Spain|Switzerland|United Kingdom | 1 |
| United States|Austria|Belgium|China|Denmark|Finland|France|Germany|Greece|Hungary|India|Ireland|Japan|Korea, Republic of|Mexico|Poland|Russian Federation|Slovakia|South Africa|Spain|Sweden|Switzerland|United Kingdom | 1 |
| United States|Austria|Belgium|China|Greece|Korea, Republic of|Portugal|Spain|Ukraine | 1 |
| United States|Austria|Belgium|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Spain|Switzerland|Taiwan | 1 |
| United States|Austria|Canada|France|Germany|Israel|Italy|Poland|Spain | 1 |
| United States|Austria|Canada|France|Germany|Israel|Korea, Republic of | 1 |
| United States|Austria|Canada|France|Germany|Spain | 1 |
| United States|Austria|Canada|Germany|Hungary|Ireland|Italy|Portugal | 1 |
| United States|Austria|China|Czechia|France|Georgia|Greece|Ireland|Italy|Korea, Republic of|Lithuania|Malaysia|Poland|Romania|Russian Federation|Slovakia|Thailand|Ukraine | 1 |
| United States|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Hungary|Italy|Mexico|Peru|Spain | 1 |
| United States|Belgium|Canada|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|Thailand|United Kingdom | 1 |
| United States|Belgium|Canada|Czechia|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain | 1 |
| United States|Belgium|Canada|France|Germany|Hong Kong|Ireland|Israel|Italy|Japan|Korea, Republic of|Lebanon|Netherlands|Portugal|Russian Federation|Singapore|Spain|Switzerland|Turkey|United Kingdom | 1 |
| United States|Belgium|Canada|France|Germany|Israel|Italy|Spain | 1 |
| United States|Belgium|Canada|France|Germany|Italy|Korea, Republic of|Poland|Spain|Sweden|Thailand|Turkey|United Kingdom | 1 |
| United States|Belgium|Canada|France|Israel|Italy|Netherlands|Spain | 1 |
| United States|Belgium|Canada|France|Italy|Poland|Spain|United Kingdom | 1 |
| United States|Belgium|Canada|Germany|Poland|United Kingdom | 1 |
| United States|Belgium|Canada|Spain | 1 |
| United States|Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom | 1 |
| United States|Belgium|China|France|Germany|Hong Kong|Japan|Korea, Republic of|Malaysia|Netherlands|Russian Federation|Singapore|Spain|Taiwan|Thailand|Vietnam | 1 |
| United States|Belgium|Denmark|France|Hungary | 1 |
| United States|Belgium|France | 1 |
| United States|Belgium|France|Germany|Greece|Israel|Netherlands|Spain | 1 |
| United States|Belgium|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Spain|United Kingdom | 1 |
| United States|Belgium|France|Germany|Italy|Netherlands|Romania|Spain | 1 |
| United States|Belgium|France|Germany|Korea, Republic of|Poland|Spain|Taiwan|United Kingdom | 1 |
| United States|Belgium|France|Italy|Spain|Taiwan|Turkey | 1 |
| United States|Belgium|France|Korea, Republic of|Spain | 1 |
| United States|Belgium|France|Netherlands|United Kingdom | 1 |
| United States|Belgium|Germany|Israel|Italy|Netherlands|Poland|Spain|United Kingdom | 1 |
| United States|Belgium|Germany|Italy|Poland|United Kingdom | 1 |
| United States|Belgium|Korea, Republic of|Netherlands|Taiwan|United Kingdom | 1 |
| United States|Belgium|United Kingdom | 1 |
| United States|Brazil | 1 |
| United States|Brazil|Bulgaria|Canada|China|Czech Republic|France|Hungary|Italy|Korea, Republic of|Latvia|Lithuania|Netherlands|Poland|Romania|Slovakia|South Africa|Taiwan|Thailand|Ukraine | 1 |
| United States|Brazil|Bulgaria|China|Germany|Hong Kong|Hungary|Japan|Korea, Republic of|Mexico|Peru|Poland|Russian Federation|South Africa|Taiwan|Thailand|Ukraine|United Kingdom|Vietnam | 1 |
| United States|Brazil|Bulgaria|France|Germany|Hungary|Netherlands|Poland | 1 |
| United States|Brazil|China|France|Germany|Greece|Hungary|Italy|Japan|Korea, Republic of|Poland|Romania|Russian Federation|Serbia|Spain|Thailand|Turkey|Ukraine|United Kingdom | 1 |
| United States|Bulgaria|Hungary|Russian Federation|Serbia | 1 |
| United States|Bulgaria|Romania | 1 |
| United States|Canada|Chile | 1 |
| United States|Canada|China|France|Hong Kong|Japan|Korea, Republic of|Singapore|Spain|Taiwan | 1 |
| United States|Canada|Czech Republic|Korea, Republic of|United Kingdom | 1 |
| United States|Canada|Denmark|France|Russian Federation | 1 |
| United States|Canada|France | 1 |
| United States|Canada|France|Germany|Greece|Hong Kong|Italy|Japan|Korea, Republic of|Romania|Spain|Taiwan|Turkey|United Kingdom | 1 |
| United States|Canada|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|United Kingdom | 1 |
| United States|Canada|France|Germany|Hungary|Japan|Poland | 1 |
| United States|Canada|France|Germany|Hungary|Spain | 1 |
| United States|Canada|France|Germany|Korea, Republic of|Netherlands|Norway|Singapore|Spain|Turkey | 1 |
| United States|Canada|France|Hong Kong|Italy|Poland|Portugal|Spain|Taiwan | 1 |
| United States|Canada|France|Italy|Portugal|Spain|Switzerland | 1 |
| United States|Canada|France|Korea, Republic of|Spain | 1 |
| United States|Canada|France|Mexico|Netherlands|Spain|Taiwan | 1 |
| United States|Canada|France|Singapore|Taiwan | 1 |
| United States|Canada|Germany | 1 |
| United States|Canada|Germany|Israel|Italy|Spain | 1 |
| United States|Canada|Germany|Israel|Netherlands|Spain | 1 |
| United States|Canada|Germany|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan | 1 |
| United States|Canada|Hong Kong | 1 |
| United States|Canada|Hong Kong|Italy|Japan|Korea, Republic of|Spain|Taiwan | 1 |
| United States|Canada|Hong Kong|Korea, Republic of|Singapore|Thailand | 1 |
| United States|Canada|Hungary|India|Netherlands|Poland|Serbia|United Kingdom | 1 |
| United States|Canada|Hungary|Israel|Spain | 1 |
| United States|Canada|Hungary|Italy|Netherlands|Poland|Romania|Spain | 1 |
| United States|Canada|Hungary|Poland|Russian Federation|Slovakia | 1 |
| United States|Canada|Ireland|Peru|South Africa | 1 |
| United States|Canada|Israel | 1 |
| United States|Canada|Israel|Italy|Poland|Romania|Russian Federation|Serbia|Spain|Switzerland|Ukraine|United Kingdom | 1 |
| United States|Canada|Italy|Spain | 1 |
| United States|Canada|Japan|Korea, Republic of|Poland|Russian Federation|Taiwan|Ukraine | 1 |
| United States|Canada|Poland | 1 |
| United States|Canada|Poland|Portugal|Spain|United Kingdom | 1 |
| United States|Canada|Saudi Arabia | 1 |
| United States|Canada|Switzerland | 1 |
| United States|Chile|Argentina|Australia|Brazil|Germany|Italy|United Kingdom | 1 |
| United States|China|Argentina|Australia|Canada|Chile|France|Germany|Israel|Japan|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|Turkey|United Kingdom | 1 |
| United States|China|Germany|Italy|Japan|Korea, Republic of|Spain|Taiwan|United Kingdom | 1 |
| United States|Czech Republic|France|Poland|Spain|United Kingdom | 1 |
| United States|Czech Republic|Greece|Hungary|Netherlands|Slovakia | 1 |
| United States|Czech Republic|Hungary | 1 |
| United States|Czechia|France|Germany|Hungary|Israel|Italy|Poland|Spain|United Kingdom | 1 |
| United States|Denmark|Japan|Korea, Republic of|Netherlands|Norway|Spain|Sweden | 1 |
| United States|Denmark|Russian Federation | 1 |
| United States|Estonia|France|Germany|Japan|Korea, Republic of|Poland|Russian Federation|United Kingdom | 1 |
| United States|Finland|France|Germany|India|Italy|South Africa|Spain|Thailand | 1 |
| United States|France|Germany|Greece|Hungary|Japan|Netherlands|Russian Federation|Spain|Taiwan|Turkey | 1 |
| United States|France|Germany|Greece|Italy|Spain | 1 |
| United States|France|Germany|Italy | 1 |
| United States|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Norway|Spain|Taiwan|United Kingdom | 1 |
| United States|France|Germany|Italy|Korea, Republic of|Portugal | 1 |
| United States|France|Germany|Italy|Spain|United Kingdom | 1 |
| United States|France|Germany|Japan|Korea, Republic of|Malaysia|Spain|Taiwan | 1 |
| United States|France|Germany|Japan|Spain|United Kingdom | 1 |
| United States|France|Germany|Spain | 1 |
| United States|France|Greece|Hungary|Italy|Korea, Republic of|Netherlands|Spain | 1 |
| United States|France|Hong Kong|Korea, Republic of|Spain|United Kingdom | 1 |
| United States|France|Israel|Japan|United Kingdom | 1 |
| United States|France|Israel|Luxembourg|Spain | 1 |
| United States|France|Israel|Spain|Taiwan | 1 |
| United States|France|Italy|Korea, Republic of|Spain|Taiwan | 1 |
| United States|France|Italy|Spain | 1 |
| United States|France|Italy|Taiwan|United Kingdom | 1 |
| United States|France|Japan|Netherlands|Spain | 1 |
| United States|France|Japan|Spain | 1 |
| United States|France|Korea, Republic of|Serbia|Spain|Taiwan | 1 |
| United States|France|Korea, Republic of|Spain|Taiwan | 1 |
| United States|France|Korea, Republic of|Spain|Turkey | 1 |
| United States|France|Netherlands | 1 |
| United States|France|Netherlands|Spain | 1 |
| United States|France|Spain | 1 |
| United States|Germany|Argentina|Austria|Belgium|Brazil|Canada|Chile|Colombia|Czech Republic|Denmark|Greece|Hong Kong|Hungary|Italy|Korea, Republic of|Netherlands|Norway|Poland|Russian Federation|Slovakia|Spain|Switzerland|Taiwan|Thailand|United Kingdom | 1 |
| United States|Germany|Australia|Belgium|Canada|China|France|Hong Kong|Hungary|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Portugal|Romania|Russian Federation|Spain|Taiwan|Ukraine|United Kingdom | 1 |
| United States|Germany|Hong Kong|Japan | 1 |
| United States|Germany|Hungary|Romania | 1 |
| United States|Germany|India|Korea, Republic of | 1 |
| United States|Germany|Italy|Korea, Republic of|Poland|Spain|Switzerland | 1 |
| United States|Germany|Italy|Spain|United Kingdom | 1 |
| United States|Germany|Japan|Korea, Republic of|Puerto Rico | 1 |
| United States|Germany|Korea, Republic of|Mexico|Poland|Russian Federation | 1 |
| United States|Germany|Korea, Republic of|Netherlands|Spain|Taiwan|United Kingdom | 1 |
| United States|Germany|Latvia|Poland|Russian Federation|Ukraine | 1 |
| United States|Germany|Puerto Rico | 1 |
| United States|Hong Kong|Korea, Republic of|Malaysia|Singapore|Taiwan|Thailand | 1 |
| United States|Hong Kong|Korea, Republic of|Singapore|Taiwan | 1 |
| United States|Hong Kong|Netherlands|Singapore|Taiwan | 1 |
| United States|Hungary|Italy|Korea, Republic of|Poland|Russian Federation|Spain|Taiwan | 1 |
| United States|Hungary|Korea, Republic of|Romania|Russian Federation|Taiwan | 1 |
| United States|Hungary|Poland|Russian Federation | 1 |
| United States|India|Poland|Romania | 1 |
| United States|India|United Kingdom | 1 |
| United States|Israel|Japan|Spain | 1 |
| United States|Israel|Spain | 1 |
| United States|Italy|Argentina|Australia|Austria|Belgium|Brazil|Canada|China|Czech Republic|Denmark|France|Germany|Greece|Hong Kong|Hungary|India|Ireland|Israel|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Singapore|Slovakia|Spain|Sweden|Switzerland|Taiwan|United Kingdom | 1 |
| United States|Italy|Japan|Poland|Romania|Russian Federation|Spain|Switzerland|Taiwan|Ukraine|United Kingdom | 1 |
| United States|Italy|Korea, Republic of|Malaysia|Spain | 1 |
| United States|Italy|Korea, Republic of|Spain | 1 |
| United States|Italy|Korea, Republic of|Taiwan | 1 |
| United States|Italy|Lithuania | 1 |
| United States|Italy|Spain | 1 |
| United States|Japan|Korea, Republic of | 1 |
| United States|Japan|Korea, Republic of|Spain|Taiwan | 1 |
| United States|Japan|Netherlands|Spain|Taiwan | 1 |
| United States|Korea, Republic of|Netherlands|Spain|Taiwan|United Kingdom | 1 |
| United States|Korea, Republic of|Spain|Taiwan | 1 |
| United States|Korea, Republic of|Taiwan | 1 |
| United States|Norway|United Kingdom | 1 |
| United States|Puerto Rico|South Africa | 1 |
| United States|Russian Federation|Ukraine | 1 |
| United States|South Africa | 1 |
| United States|Switzerland | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 918 |
| 2 | 165 |
| 3 | 88 |
| 4 | 80 |
| 5 | 75 |
| 6 | 33 |
| 7 | 56 |
| 8 | 39 |
| 9 | 35 |
| 10 | 38 |
| 11 | 29 |
| 12 | 33 |
| 13 | 30 |
| 14 | 18 |
| 15 | 24 |
| 16 | 28 |
| 17 | 15 |
| 18 | 12 |
| 19 | 19 |
| 20 | 21 |
| 21 | 18 |
| 22 | 12 |
| 23 | 11 |
| 24 | 14 |
| 25 | 13 |
| 26 | 10 |
| 27 | 7 |
| 28 | 9 |
| 29 | 7 |
| 30 | 14 |
| 31 | 9 |
| 32 | 9 |
| 33 | 11 |
| 34 | 4 |
| 35 | 8 |
| 36 | 6 |
| 37 | 8 |
| 38 | 10 |
| 39 | 4 |
| 40 | 5 |
| 41 | 3 |
| 42 | 10 |
| 43 | 4 |
| 44 | 11 |
| 45 | 3 |
| 46 | 4 |
| 47 | 8 |
| 48 | 3 |
| 49 | 1 |
| 50 | 5 |
| 51 | 4 |
| 52 | 7 |
| 53 | 2 |
| 54 | 2 |
| 55 | 2 |
| 56 | 4 |
| 57 | 3 |
| 58 | 2 |
| 59 | 5 |
| 60 | 6 |
| 61 | 1 |
| 62 | 2 |
| 63 | 1 |
| 64 | 3 |
| 65 | 4 |
| 66 | 2 |
| 67 | 2 |
| 68 | 2 |
| 69 | 7 |
| 70 | 3 |
| 71 | 4 |
| 72 | 4 |
| 73 | 3 |
| 74 | 4 |
| 75 | 2 |
| 76 | 2 |
| 77 | 1 |
| 78 | 3 |
| 79 | 3 |
| 80 | 2 |
| 81 | 1 |
| 82 | 1 |
| 84 | 5 |
| 85 | 3 |
| 86 | 3 |
| 87 | 2 |
| 88 | 2 |
| 89 | 1 |
| 90 | 3 |
| 91 | 3 |
| 92 | 3 |
| 93 | 4 |
| 94 | 3 |
| 96 | 1 |
| 97 | 1 |
| 98 | 1 |
| 99 | 1 |
| 101 | 4 |
| 103 | 1 |
| 105 | 3 |
| 108 | 1 |
| 109 | 1 |
| 110 | 3 |
| 111 | 1 |
| 112 | 1 |
| 113 | 2 |
| 114 | 2 |
| 115 | 2 |
| 116 | 1 |
| 117 | 3 |
| 118 | 2 |
| 119 | 1 |
| 120 | 2 |
| 121 | 1 |
| 122 | 1 |
| 123 | 4 |
| 124 | 2 |
| 125 | 1 |
| 126 | 1 |
| 127 | 1 |
| 129 | 1 |
| 132 | 1 |
| 133 | 5 |
| 134 | 1 |
| 135 | 2 |
| 136 | 1 |
| 137 | 1 |
| 139 | 1 |
| 140 | 1 |
| 141 | 4 |
| 143 | 2 |
| 144 | 1 |
| 145 | 1 |
| 147 | 2 |
| 148 | 1 |
| 150 | 1 |
| 152 | 1 |
| 153 | 1 |
| 154 | 3 |
| 155 | 3 |
| 156 | 1 |
| 157 | 2 |
| 158 | 1 |
| 160 | 1 |
| 161 | 1 |
| 162 | 2 |
| 163 | 1 |
| 166 | 1 |
| 167 | 2 |
| 168 | 1 |
| 170 | 1 |
| 175 | 1 |
| 179 | 1 |
| 181 | 1 |
| 182 | 3 |
| 183 | 1 |
| 185 | 1 |
| 186 | 1 |
| 187 | 1 |
| 188 | 2 |
| 189 | 2 |
| 192 | 1 |
| 196 | 1 |
| 197 | 1 |
| 199 | 1 |
| 200 | 1 |
| 204 | 1 |
| 207 | 1 |
| 208 | 1 |
| 210 | 2 |
| 212 | 1 |
| 213 | 2 |
| 216 | 1 |
| 224 | 2 |
| 227 | 1 |
| 228 | 1 |
| 230 | 1 |
| 231 | 2 |
| 233 | 1 |
| 237 | 1 |
| 240 | 2 |
| 242 | 1 |
| 247 | 2 |
| 248 | 1 |
| 249 | 1 |
| 257 | 1 |
| 260 | 1 |
| 263 | 1 |
| 264 | 2 |
| 271 | 1 |
| 279 | 1 |
| 287 | 1 |
| 295 | 2 |
| 301 | 1 |
| 305 | 1 |
| 332 | 1 |
| 339 | 1 |
| 348 | 1 |
| 369 | 2 |
| 386 | 1 |
| 418 | 1 |
| 457 | 1 |
| 468 | 1 |
| 484 | 1 |
| 532 | 1 |
| 544 | 1 |
| 605 | 1 |
| 638 | 1 |
| 658 | 1 |
| 743 | 1 |
| 873 | 1 |
| 892 | 1 |
| 931 | 1 |
| 1175 | 1 |
| 1498 | 2 |
| Phase | Study_Count |
|---|---|
| Phase 2 | 1017 |
| Phase 1 | 423 |
| Phase 3 | 359 |
| Phase 1/Phase 2 | 228 |
| N/A | 180 |
| Phase 4 | 43 |
| Phase 2/Phase 3 | 28 |
| Early Phase 1 | 16 |
| Number_of_Arms | Count_of_Studies |
|---|---|
| 1 | 945 |
| 2 | 798 |
| 3 | 151 |
| 4 | 81 |
| 5 | 22 |
| 6 | 18 |
| 7 | 11 |
| 8 | 5 |
| 9 | 8 |
| 10 | 5 |
| 11 | 2 |
| 12 | 1 |
| 13 | 1 |
| 14 | 2 |
| 15 | 1 |
| 16 | 1 |
| 18 | 2 |
| 19 | 1 |
| 24 | 1 |
| NA | 238 |
| Measure | Early.Phase.1 | N.A | Phase.1 | Phase.1.Phase.2 | Phase.2 | Phase.2.Phase.3 | Phase.3 | Phase.4 |
|---|---|---|---|---|---|---|---|---|
| Min. | 3.0 | 3.0000 | 1.00000 | 2.0000 | 1.00000 | 40.0000 | 1.000 | 5.0000 |
| 1st Qu. | 12.0 | 29.0000 | 18.00000 | 40.0000 | 40.00000 | 116.0000 | 275.750 | 53.0000 |
| Median | 22.5 | 58.0000 | 31.00000 | 70.0000 | 65.00000 | 187.0000 | 453.500 | 107.5000 |
| Mean | 32.5 | 443.8371 | 60.51074 | 103.5946 | 97.38641 | 634.7857 | 550.321 | 384.6905 |
| 3rd Qu. | 32.0 | 150.7500 | 56.50000 | 122.5000 | 120.00000 | 409.7500 | 671.500 | 195.0000 |
| Max. | 180.0 | 39981.0000 | 1260.00000 | 970.0000 | 1805.00000 | 10000.0000 | 5000.000 | 6586.0000 |
| group_type | Group_Count |
|---|---|
| Experimental | 3086 |
| Active Comparator | 560 |
| NA | 238 |
| Placebo Comparator | 167 |
| Other | 99 |
| No Intervention | 45 |
| Sham Comparator | 3 |
| intervention_model | Study_Count |
|---|---|
| Single Group Assignment | 1113 |
| Parallel Assignment | 997 |
| NA | 93 |
| Sequential Assignment | 58 |
| Crossover Assignment | 27 |
| Factorial Assignment | 6 |
| primary_purpose | Study_Count |
|---|---|
| Treatment | 2123 |
| Diagnostic | 61 |
| Supportive Care | 34 |
| Other | 30 |
| Prevention | 14 |
| Basic Science | 11 |
| NA | 8 |
| Health Services Research | 6 |
| Screening | 6 |
| Device Feasibility | 1 |
| Country | Study_Count |
|---|---|
| China | 58 |
| United States | 54 |
| France | 29 |
| NA | 19 |
| Germany | 12 |
| Netherlands | 11 |
| Spain | 10 |
| Korea, Republic of | 9 |
| Japan | 8 |
| Taiwan | 8 |
| Canada | 7 |
| Belgium | 5 |
| Denmark | 5 |
| Italy | 5 |
| United Kingdom | 5 |
| Greece | 4 |
| United States|Canada | 4 |
| Austria | 3 |
| Mexico | 3 |
| Poland | 3 |
| Singapore | 3 |
| Brazil | 2 |
| Egypt | 2 |
| Ireland | 2 |
| Russian Federation | 2 |
| Argentina | 1 |
| Argentina|Chile|Colombia|Dominican Republic|India|Mexico|Peru|Taiwan|Thailand|Uruguay | 1 |
| Argentina|Chile|Colombia|Uruguay | 1 |
| Australia | 1 |
| Australia|Belgium|France|Germany|Israel|Italy|Netherlands|Norway|Switzerland|United Kingdom | 1 |
| Australia|New Zealand|Singapore | 1 |
| Austria|Belgium|Denmark|Germany|Greece|Hungary|Italy|Lithuania|Luxembourg|Netherlands|Spain|Sweden|United Kingdom | 1 |
| Austria|Belgium|Germany|Spain|Switzerland | 1 |
| Austria|Germany | 1 |
| Bahrain|Qatar|United Arab Emirates | 1 |
| Belgium|France|Germany|Greece|Italy|Portugal|Spain|Turkey | 1 |
| China|Japan|Korea, Republic of | 1 |
| Czechia|Germany|Poland|Spain|Switzerland|United Kingdom | 1 |
| Egypt|Lebanon|Morocco|Saudi Arabia|United Arab Emirates | 1 |
| Finland | 1 |
| Hong Kong|Korea, Republic of|Malaysia|Singapore | 1 |
| Hungary | 1 |
| India | 1 |
| Jordan | 1 |
| Kazakhstan | 1 |
| Korea, Republic of|Singapore | 1 |
| Norway | 1 |
| Serbia | 1 |
| Sweden | 1 |
| United States|Austria|Canada|France|Germany|Italy|Japan|Korea, Republic of|Mexico|Poland|Singapore|Spain|Taiwan | 1 |
| United States|Bolivia|Mexico|Peru|Venezuela | 1 |
| United States|Denmark | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 176 |
| 2 | 8 |
| 3 | 8 |
| 4 | 7 |
| 5 | 9 |
| 6 | 5 |
| 7 | 3 |
| 8 | 3 |
| 9 | 5 |
| 10 | 9 |
| 11 | 5 |
| 12 | 2 |
| 13 | 1 |
| 14 | 4 |
| 15 | 2 |
| 17 | 2 |
| 18 | 1 |
| 21 | 1 |
| 22 | 2 |
| 23 | 4 |
| 24 | 2 |
| 25 | 1 |
| 26 | 2 |
| 28 | 1 |
| 29 | 2 |
| 31 | 2 |
| 32 | 2 |
| 33 | 2 |
| 35 | 1 |
| 37 | 1 |
| 39 | 1 |
| 41 | 1 |
| 42 | 1 |
| 43 | 1 |
| 44 | 1 |
| 46 | 1 |
| 50 | 1 |
| 56 | 1 |
| 61 | 1 |
| 63 | 1 |
| 71 | 1 |
| 72 | 1 |
| 73 | 1 |
| 81 | 1 |
| 88 | 1 |
| 92 | 1 |
| 101 | 1 |
| 111 | 1 |
| 118 | 1 |
| 120 | 1 |
| 133 | 1 |
| 152 | 1 |
| 170 | 1 |
| 198 | 1 |
| 299 | 1 |
| 405 | 1 |
| 432 | 1 |
| Measure | Observational |
|---|---|
| Min | 1.0000 |
| 1st Qu | 70.0000 |
| Median | 165.0000 |
| Mean | 782.3345 |
| 3rd Qu | 503.2500 |
| Max | 50000.0000 |
| observational_model | Study_Count |
|---|---|
| Cohort | 188 |
| Case-Only | 66 |
| Other | 17 |
| NA | 10 |
| Case-Control | 9 |
| Case Control | 6 |
| Case-Crossover | 2 |
| Defined Population | 1 |
| Ecologic or Community | 1 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 188 |
| Retrospective | 87 |
| Cross-Sectional | 14 |
| Other | 7 |
| NA | 3 |
| Longitudinal, Prospective | 1 |
| Country | Study_Count |
|---|---|
| China | 7 |
| Korea, Republic of | 3 |
| Belgium | 2 |
| Germany | 2 |
| Greece | 2 |
| Japan | 2 |
| NA | 2 |
| Denmark|Norway | 1 |
| Egypt | 1 |
| France | 1 |
| Netherlands | 1 |
| United Kingdom | 1 |
| United States | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 19 |
| 2 | 1 |
| 5 | 1 |
| 8 | 1 |
| 34 | 1 |
| 44 | 2 |
| 73 | 1 |
| Measure | Registries |
|---|---|
| Min | 20.000 |
| 1st Qu | 132.000 |
| Median | 315.000 |
| Mean | 1034.808 |
| 3rd Qu | 989.000 |
| Max | 7500.000 |
| observational_model | Study_Count |
|---|---|
| Cohort | 20 |
| Other | 4 |
| Case-Only | 2 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 21 |
| Other | 5 |
| target_duration | Study_Count |
|---|---|
| 3 Years | 11 |
| 5 Years | 4 |
| 1 Year | 2 |
| 24 Months | 2 |
| 1 Day | 1 |
| 12 Months | 1 |
| 2 Years | 1 |
| 20 Months | 1 |
| 36 Months | 1 |
| 4 Months | 1 |
| 7 Years | 1 |
#If less then 500 trials
#If less then 500 studies
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT04455984 | Multimodality Treatment Including Curative Resection of Advanced NSCLC | https://ClinicalTrials.gov/show/NCT04455984 | Recruiting | Medical University of Vienna | 2020-08-01 |
| NCT04165798 | Umbrella Master Protocol: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYNOTE-U01) | https://ClinicalTrials.gov/show/NCT04165798 | Recruiting | Merck Sharp & Dohme Corp. | 2032-02-13 |
| NCT03389399 | Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases | https://ClinicalTrials.gov/show/NCT03389399 | Recruiting | University of Colorado, Denver | 2021-08-30 |
| NCT03375242 | Safety and Efficacy of Xalkori ROS1 | https://ClinicalTrials.gov/show/NCT03375242 | Recruiting | Pfizer | 2022-03-14 |
| NCT03373955 | A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients | https://ClinicalTrials.gov/show/NCT03373955 | Recruiting | Sichuan University | 2020-07-31 |
| NCT03370770 | Afatinib Osimertinib Sequencing NIS | https://ClinicalTrials.gov/show/NCT03370770 | Completed | Boehringer Ingelheim | 2019-11-28 |
| NCT03816657 | The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT03816657 | Active, not recruiting | Fondazione Ricerca Traslazionale | 2017-05-15 |
| NCT03363685 | Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis | https://ClinicalTrials.gov/show/NCT03363685 | Recruiting | Ruijin Hospital | 2022-11-01 |
| NCT03289780 | Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects | https://ClinicalTrials.gov/show/NCT03289780 | Recruiting | Biodesix, Inc. | 2019-06-30 |
| NCT03273790 | A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan | https://ClinicalTrials.gov/show/NCT03273790 | Active, not recruiting | Bristol-Myers Squibb | 2019-10-31 |
| NCT03271554 | Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea | https://ClinicalTrials.gov/show/NCT03271554 | Recruiting | Hoffmann-La Roche | 2021-12-31 |
| NCT03258788 | A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03258788 | Recruiting | The Christie NHS Foundation Trust | 2019-12-31 |
| NCT03236675 | Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients | https://ClinicalTrials.gov/show/NCT03236675 | Active, not recruiting | Exosome Diagnostics, Inc. | 2020-02-29 |
| NCT03219970 | Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting. | https://ClinicalTrials.gov/show/NCT03219970 | Active, not recruiting | AstraZeneca | 2020-05-31 |
| NCT03216551 | Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC | https://ClinicalTrials.gov/show/NCT03216551 | Recruiting | Fudan University | 2021-04-01 |
| NCT03199599 | Prognostic PET/CT Model in Non Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03199599 | Completed | Poitiers University Hospital | 2019-08-31 |
| NCT03170284 | Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03170284 | Completed | Hoffmann-La Roche | 2012-08-01 |
| NCT03137264 | Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients | https://ClinicalTrials.gov/show/NCT03137264 | Completed | AstraZeneca | 2018-11-10 |
| NCT03141957 | Hypermetabolism in the Elderly Lung Cancer Patient | https://ClinicalTrials.gov/show/NCT03141957 | Completed | University of Paris 5 - Rene Descartes | 2016-11-30 |
| NCT03132493 | Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient | https://ClinicalTrials.gov/show/NCT03132493 | Completed | Spanish Lung Cancer Group | 2017-12-01 |
| NCT03133234 | Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC | https://ClinicalTrials.gov/show/NCT03133234 | Completed | AstraZeneca | 2017-09-13 |
| NCT03130192 | A Study of the Correlation Between CRF, Survival and Physiological Factors in NSCLC Patients Under Chemotherapy | https://ClinicalTrials.gov/show/NCT03130192 | Recruiting | Chung Shan Medical University | 2021-06-07 |
| NCT03092739 | A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens | https://ClinicalTrials.gov/show/NCT03092739 | Completed | Hoffmann-La Roche | 2018-01-08 |
| NCT03059641 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China | https://ClinicalTrials.gov/show/NCT03059641 | Completed | Geneplus-Beijing Co. Ltd. | 2019-12-31 |
| NCT03055715 | Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC | https://ClinicalTrials.gov/show/NCT03055715 | Completed | Martin-Luther-Universität Halle-Wittenberg | 2018-04-01 |
| NCT03042221 | Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy | https://ClinicalTrials.gov/show/NCT03042221 | Recruiting | University of Colorado, Denver | 2020-09-30 |
| NCT03037086 | Asia PDL1 Study Among NSCLC Patients | https://ClinicalTrials.gov/show/NCT03037086 | Completed | AstraZeneca | 2017-02-27 |
| NCT02980536 | cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | https://ClinicalTrials.gov/show/NCT02980536 | Active, not recruiting | Berry Genomics Co., Ltd. | 2018-10-31 |
| NCT02972216 | Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy | https://ClinicalTrials.gov/show/NCT02972216 | Completed | Yung Shin Pharm. Ind. Co., Ltd. | 2016-10-31 |
| NCT02968979 | Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer. | https://ClinicalTrials.gov/show/NCT02968979 | Completed | Chugai Pharma France | 2016-10-31 |
| NCT02966769 | N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation | https://ClinicalTrials.gov/show/NCT02966769 | Completed | Grupo de Investigación ClÃnica en OncologÃa Radioterapia | 2017-03-31 |
| NCT03232593 | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | https://ClinicalTrials.gov/show/NCT03232593 | Recruiting | Hoffmann-La Roche | 2023-01-11 |
| NCT02932345 | Gefitinib Long-term Survivor Study | https://ClinicalTrials.gov/show/NCT02932345 | Completed | AstraZeneca | 2017-07-04 |
| NCT02933346 | Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program | https://ClinicalTrials.gov/show/NCT02933346 | Active, not recruiting | Intergroupe Francophone de Cancerologie Thoracique | 2018-01-31 |
| NCT02910999 | Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy | https://ClinicalTrials.gov/show/NCT02910999 | Active, not recruiting | Bristol-Myers Squibb | 2023-12-31 |
| NCT02906852 | Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing | https://ClinicalTrials.gov/show/NCT02906852 | Completed | Inivata | 2018-05-31 |
| NCT02848872 | Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT02848872 | Completed | Duke University | 2019-04-02 |
| NCT02827344 | PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT02827344 | Recruiting | University Hospital, Toulouse | 2019-10-31 |
| NCT02799862 | Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC | https://ClinicalTrials.gov/show/NCT02799862 | Active, not recruiting | iOMEDICO AG | 2019-12-07 |
| NCT02777567 | KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy) | https://ClinicalTrials.gov/show/NCT02777567 | Completed | AstraZeneca | 2020-03-19 |
| NCT02764606 | CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT02764606 | Recruiting | Hospices Civils de Lyon | 2025-12-31 |
| NCT02740894 | Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ? | https://ClinicalTrials.gov/show/NCT02740894 | Completed | Taipei Veterans General Hospital, Taiwan | 2016-04-30 |
| NCT02727335 | Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements | https://ClinicalTrials.gov/show/NCT02727335 | Completed | Intergroupe Francophone de Cancerologie Thoracique | 2015-12-31 |
| NCT02718651 | Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer | https://ClinicalTrials.gov/show/NCT02718651 | Completed | University of Aarhus | 2018-12-31 |
| NCT02714335 | The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients | https://ClinicalTrials.gov/show/NCT02714335 | Completed | National Taiwan University | 2013-11-30 |
| NCT02695849 | A Study of Prevalence of EGFR Mutations in Participants With NSCLC | https://ClinicalTrials.gov/show/NCT02695849 | Completed | Hoffmann-La Roche | 2015-05-31 |
| NCT02679170 | Prospective Observational Study To Identify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) And ALK Translocation And To Establish Their Therapeutic Management (IDEALK) | https://ClinicalTrials.gov/show/NCT02679170 | Recruiting | Pfizer | 2020-06-30 |
| NCT02671422 | LUME BioNIS: a Biomarker Study in Patients With NSCLC | https://ClinicalTrials.gov/show/NCT02671422 | Completed | Boehringer Ingelheim | 2019-09-03 |
| NCT02658747 | Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK | https://ClinicalTrials.gov/show/NCT02658747 | Completed | Hoffmann-La Roche | 2016-07-25 |
| NCT02645318 | Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT02645318 | Completed | Peking University People’s Hospital | 2015-07-31 |
| NCT02623257 | EGFR Mutations on ctDNA in Patients With Advanced NSCLC | https://ClinicalTrials.gov/show/NCT02623257 | Completed | First People’s Hospital of Hangzhou | 2017-07-31 |
| NCT02619929 | Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria | https://ClinicalTrials.gov/show/NCT02619929 | Completed | Pierre Fabre Pharma GmbH | 2018-03-31 |
| NCT02620657 | Evaluate EGFR Mutation Status and Impact Factors in North China | https://ClinicalTrials.gov/show/NCT02620657 | Completed | Guangdong Association of Clinical Trials | 2017-11-08 |
| NCT02595450 | A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT02595450 | Completed | Hoffmann-La Roche | 2014-11-30 |
| NCT02575560 | Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT02575560 | Completed | Qingdao Central Hospital | 2017-09-30 |
| NCT02038413 | State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients | https://ClinicalTrials.gov/show/NCT02038413 | Completed | Maastricht Radiation Oncology | 2014-10-31 |
| NCT02146170 | Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors | https://ClinicalTrials.gov/show/NCT02146170 | Recruiting | National Institutes of Health Clinical Center (CC) | 2024-04-30 |
| NCT02321046 | An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer). | https://ClinicalTrials.gov/show/NCT02321046 | Completed | AstraZeneca | 2019-06-28 |
| NCT02511288 | LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT02511288 | Recruiting | Centre Leon Berard | 2026-03-31 |
| NCT02475720 | Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC) | https://ClinicalTrials.gov/show/NCT02475720 | Completed | AstraZeneca | 2016-03-16 |
| NCT02458651 | Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China | https://ClinicalTrials.gov/show/NCT02458651 | Completed | Hoffmann-La Roche | 2018-10-30 |
| NCT02445924 | Micro RNA Genetic Signature in NSCLC Egyptian Patients | https://ClinicalTrials.gov/show/NCT02445924 | Completed | Tanta University | 2016-01-31 |
| NCT02428049 | Lung Function Changes After Curative Targeted Radiotherapy of Non-small-cell Lung Carcinoma | https://ClinicalTrials.gov/show/NCT02428049 | Recruiting | Sykehuset i Vestfold HF | 2018-12-31 |
| NCT02418234 | T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure | https://ClinicalTrials.gov/show/NCT02418234 | Completed | First People’s Hospital of Hangzhou | 2016-04-30 |
| NCT02410603 | Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer | https://ClinicalTrials.gov/show/NCT02410603 | Recruiting | Mayo Clinic | 2020-06-30 |
| NCT02392455 | VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT02392455 | Recruiting | Boehringer Ingelheim | 2022-12-31 |
| NCT02380196 | The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT02380196 | Completed | Abramson Cancer Center of the University of Pennsylvania | 2019-12-31 |
| NCT02370303 | A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System | https://ClinicalTrials.gov/show/NCT02370303 | Completed | Mayo Clinic | 2016-07-09 |
| NCT02338583 | Powered Surgical Stapler in VATS Lung Resection Procedures in China | https://ClinicalTrials.gov/show/NCT02338583 | Completed | Ethicon Endo-Surgery | 2015-04-01 |
| NCT02304406 | Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa | https://ClinicalTrials.gov/show/NCT02304406 | Completed | Pfizer | 2018-02-11 |
| NCT02293733 | Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) | https://ClinicalTrials.gov/show/NCT02293733 | Completed | Groupe Francais De Pneumo-Cancerologie | 2014-03-31 |
| NCT02285361 | GIOTRIF rPMS in Korean Patients With NSCLC | https://ClinicalTrials.gov/show/NCT02285361 | Completed | Boehringer Ingelheim | 2019-12-31 |
| NCT02271581 | Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer | https://ClinicalTrials.gov/show/NCT02271581 | Recruiting | Leo W. Jenkins Cancer Center | 2020-07-31 |
| NCT02245100 | Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT02245100 | Recruiting | Thomas Jefferson University | 2020-07-31 |
| NCT02196675 | Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea | https://ClinicalTrials.gov/show/NCT02196675 | Completed | Ethicon Endo-Surgery | 2015-01-31 |
| NCT02169349 | Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT02169349 | Completed | Rennes University Hospital | 2016-06-30 |
| NCT02171286 | The Oncopanel Pilot (TOP) Study | https://ClinicalTrials.gov/show/NCT02171286 | Completed | British Columbia Cancer Agency | 2017-03-31 |
| NCT02133508 | A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib) | https://ClinicalTrials.gov/show/NCT02133508 | Completed | Hoffmann-La Roche | 2016-06-10 |
| NCT02131259 | Long-term Observation PMS for Afatinib | https://ClinicalTrials.gov/show/NCT02131259 | Completed | Boehringer Ingelheim | 2016-12-28 |
| NCT02109549 | Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients. | https://ClinicalTrials.gov/show/NCT02109549 | Completed | Maastricht Radiation Oncology | 2015-12-31 |
| NCT01300429 | Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus | https://ClinicalTrials.gov/show/NCT01300429 | Active, not recruiting | Memorial Sloan Kettering Cancer Center | 2021-02-28 |
| NCT01290809 | Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients | https://ClinicalTrials.gov/show/NCT01290809 | Completed | Maastricht Radiation Oncology | 2015-03-31 |
| NCT01294280 | Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy | https://ClinicalTrials.gov/show/NCT01294280 | Recruiting | Alliance for Clinical Trials in Oncology | 2100-01-31 |
| NCT01279408 | Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC) | https://ClinicalTrials.gov/show/NCT01279408 | Active, not recruiting | University Health Network, Toronto | 2028-11-30 |
| NCT02047903 | GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations | https://ClinicalTrials.gov/show/NCT02047903 | Completed | Boehringer Ingelheim | 2018-12-31 |
| NCT02042105 | A Prospective Epidemiologic Study of ALK-Positive NSCLC in China | https://ClinicalTrials.gov/show/NCT02042105 | Completed | Guangdong Association of Clinical Trials | 2015-04-15 |
| NCT01991418 | Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) | https://ClinicalTrials.gov/show/NCT01991418 | Completed | Hunan Province Tumor Hospital | 2016-02-29 |
| NCT01994057 | A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in NSCLC Patients Treatment | https://ClinicalTrials.gov/show/NCT01994057 | Recruiting | Sun Yat-sen University | 2021-10-31 |
| NCT01985113 | Correlation Research of Thioredoxin Reductase in Lung Cancer | https://ClinicalTrials.gov/show/NCT01985113 | Completed | Hunan Province Tumor Hospital | 2016-02-29 |
| NCT01980212 | Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01980212 | Completed | Hunan Province Tumor Hospital | 2016-12-01 |
| NCT01956331 | Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer | https://ClinicalTrials.gov/show/NCT01956331 | Completed | Groupe Francais De Pneumo-Cancerologie | 2013-06-30 |
| NCT01947868 | Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor | https://ClinicalTrials.gov/show/NCT01947868 | Completed | AstraZeneca | 2015-09-30 |
| NCT01941303 | Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent Disease | https://ClinicalTrials.gov/show/NCT01941303 | Completed | Maastricht Radiation Oncology | 2015-09-30 |
| NCT01934465 | Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment | https://ClinicalTrials.gov/show/NCT01934465 | Completed | Hellenic Oncology Research Group | 2013-12-31 |
| NCT01893268 | An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice | https://ClinicalTrials.gov/show/NCT01893268 | Completed | Hoffmann-La Roche | 2018-03-20 |
| NCT04351334 | Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns | https://ClinicalTrials.gov/show/NCT04351334 | Active, not recruiting | Pfizer | 2020-07-31 |
| NCT01888601 | TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) | https://ClinicalTrials.gov/show/NCT01888601 | Recruiting | University College, London | 2023-11-30 |
| NCT01843192 | Powered Echelon Device in VATS Surgery | https://ClinicalTrials.gov/show/NCT01843192 | Completed | Ethicon Endo-Surgery | 2014-05-31 |
| NCT01837511 | Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients | https://ClinicalTrials.gov/show/NCT01837511 | Completed | GlaxoSmithKline | 2008-01-31 |
| NCT01837186 | Empyema Following Pneumonectomy for Non Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT01837186 | Completed | University Hospital, Gasthuisberg | 2012-09-30 |
| NCT01836133 | An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) | https://ClinicalTrials.gov/show/NCT01836133 | Completed | Hoffmann-La Roche | 2016-01-31 |
| NCT01830426 | Circulating Tumor Cells in Non-Small Cell Lung Carcinoma | https://ClinicalTrials.gov/show/NCT01830426 | Completed | Epic Sciences | 2015-12-31 |
| NCT01790217 | An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC) | https://ClinicalTrials.gov/show/NCT01790217 | Completed | Hoffmann-La Roche | 2013-08-31 |
| NCT01795352 | Retrospective Study in a NSCLC M+ p | https://ClinicalTrials.gov/show/NCT01795352 | Completed | AstraZeneca | 2013-10-31 |
| NCT01772225 | NSCLC Burden of Illness Study | https://ClinicalTrials.gov/show/NCT01772225 | Completed | GlaxoSmithKline | 2014-01-31 |
| NCT01740804 | Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC | https://ClinicalTrials.gov/show/NCT01740804 | Completed | Guangdong Association of Clinical Trials | 2016-04-30 |
| NCT01726309 | Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 | https://ClinicalTrials.gov/show/NCT01726309 | Active, not recruiting | Cancer Trials Ireland | 2024-08-31 |
| NCT01723878 | ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations | https://ClinicalTrials.gov/show/NCT01723878 | Completed | Hoffmann-La Roche | 2017-06-20 |
| NCT01721252 | Tarceva. ICORG 08-41 | https://ClinicalTrials.gov/show/NCT01721252 | Completed | Cancer Trials Ireland | 2013-08-31 |
| NCT01700582 | French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | https://ClinicalTrials.gov/show/NCT01700582 | Completed | Intergroupe Francophone de Cancerologie Thoracique | 2013-04-30 |
| NCT01662635 | Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK) | https://ClinicalTrials.gov/show/NCT01662635 | Completed | Instituto Nacional de Cancerologia de Mexico | 2014-09-30 |
| NCT01664533 | An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy | https://ClinicalTrials.gov/show/NCT01664533 | Completed | Hoffmann-La Roche | 2013-08-31 |
| NCT01659970 | PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01659970 | Completed | Hoffmann-La Roche | 2014-04-30 |
| NCT01660776 | BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology | https://ClinicalTrials.gov/show/NCT01660776 | Completed | Rennes University Hospital | 2017-10-02 |
| NCT01630122 | Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates | https://ClinicalTrials.gov/show/NCT01630122 | Completed | Wake Forest University Health Sciences | 2015-08-18 |
| NCT01620853 | Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test) | https://ClinicalTrials.gov/show/NCT01620853 | Completed | Applied Spectral Imaging Ltd. | 2013-01-31 |
| NCT01598597 | An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) | https://ClinicalTrials.gov/show/NCT01598597 | Completed | Genentech, Inc. | 2014-11-30 |
| NCT01597258 | Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan) | https://ClinicalTrials.gov/show/NCT01597258 | Completed | Pfizer | 2018-03-16 |
| NCT04018183 | The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT04018183 | Completed | National Taiwan University Hospital | 2020-03-24 |
| NCT01562665 | Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf | https://ClinicalTrials.gov/show/NCT01562665 | Completed | AstraZeneca | 2015-02-28 |
| NCT01551251 | Tumor Associated Macrophage in Advanced Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01551251 | Completed | Chang Gung Memorial Hospital | 2010-12-31 |
| NCT01540045 | Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01540045 | Completed | Instituto Nacional de Cancerologia de Mexico | 2011-12-31 |
| NCT01535729 | An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01535729 | Completed | Hoffmann-La Roche | 2014-06-30 |
| NCT01525199 | Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations. | https://ClinicalTrials.gov/show/NCT01525199 | Completed | AstraZeneca | 2013-11-30 |
| NCT01512420 | An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT) | https://ClinicalTrials.gov/show/NCT01512420 | Completed | Hoffmann-La Roche | 2015-02-28 |
| NCT01510405 | Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01510405 | Active, not recruiting | Dartmouth-Hitchcock Medical Center | 2020-12-31 |
| NCT01488331 | An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01488331 | Completed | Hoffmann-La Roche | 2013-11-30 |
| NCT01482182 | Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy | https://ClinicalTrials.gov/show/NCT01482182 | Completed | Samsung Medical Center | 2013-11-30 |
| NCT01385722 | Molecular Analysis of Thoracic Malignancies | https://ClinicalTrials.gov/show/NCT01385722 | Enrolling by invitation | Stanford University | 2031-06-30 |
| NCT01358942 | An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab) | https://ClinicalTrials.gov/show/NCT01358942 | Completed | Hoffmann-La Roche | 2012-11-30 |
| NCT01346280 | Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs | https://ClinicalTrials.gov/show/NCT01346280 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT01343914 | An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy | https://ClinicalTrials.gov/show/NCT01343914 | Completed | Hoffmann-La Roche | 2011-12-31 |
| NCT01333007 | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01333007 | Completed | Hoffmann-La Roche | 2013-05-31 |
| NCT04430725 | Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study | https://ClinicalTrials.gov/show/NCT04430725 | Recruiting | M.D. Anderson Cancer Center | 2023-01-01 |
| NCT04430712 | Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume | https://ClinicalTrials.gov/show/NCT04430712 | Active, not recruiting | Massachusetts General Hospital | 2021-03-31 |
| NCT04405661 | Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC | https://ClinicalTrials.gov/show/NCT04405661 | Recruiting | Guangzhou Institute of Respiratory Disease | 2021-05-31 |
| NCT04324164 | Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC | https://ClinicalTrials.gov/show/NCT04324164 | Recruiting | Hunan Province Tumor Hospital | 2021-03-24 |
| NCT04324151 | Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC | https://ClinicalTrials.gov/show/NCT04324151 | Recruiting | Hunan Province Tumor Hospital | 2021-03-24 |
| NCT04324125 | Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC | https://ClinicalTrials.gov/show/NCT04324125 | Recruiting | Hunan Province Tumor Hospital | 2021-03-24 |
| NCT04322890 | PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene Mutation Positive Advanced NSCLC | https://ClinicalTrials.gov/show/NCT04322890 | Recruiting | Hunan Province Tumor Hospital | 2021-03-24 |
| NCT04322617 | Anlotinib Plus PD-1 Antibody in Standard Chemotherapy Failure Advanced NSCLC: the ATHENA Study | https://ClinicalTrials.gov/show/NCT04322617 | Recruiting | Hunan Province Tumor Hospital | 2021-03-24 |
| NCT04322591 | Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial | https://ClinicalTrials.gov/show/NCT04322591 | Recruiting | Hunan Province Tumor Hospital | 2021-03-24 |
| NCT04322578 | Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC | https://ClinicalTrials.gov/show/NCT04322578 | Recruiting | Hunan Province Tumor Hospital | 2021-03-24 |
| NCT04317651 | Crizotinib in ALK Rearranged Non-small-cell Lung Cancer | https://ClinicalTrials.gov/show/NCT04317651 | Recruiting | Fondazione Ricerca Traslazionale | 2021-12-31 |
| NCT04309422 | Texture Features and PDL1 in CT-PET 18 FDG | https://ClinicalTrials.gov/show/NCT04309422 | Completed | University Hospital, Montpellier | 2018-10-01 |
| NCT04291755 | Development and Analysis of a Stool Bank for Cancer Patients | https://ClinicalTrials.gov/show/NCT04291755 | Recruiting | Persephone Biosciences | 2020-12-31 |
| NCT04257864 | Bevacizumab Versus Docetaxel/Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT04257864 | Completed | Hellenic Cooperative Oncology Group | 2010-05-31 |
| NCT04238130 | Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection | https://ClinicalTrials.gov/show/NCT04238130 | Recruiting | Sun Yat-sen University | 2022-12-18 |
| NCT04207775 | Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy | https://ClinicalTrials.gov/show/NCT04207775 | Recruiting | AstraZeneca | 2023-05-30 |
| NCT04206787 | The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT04206787 | Recruiting | Boehringer Ingelheim | 2023-12-15 |
| NCT04208854 | Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT04208854 | Recruiting | International Group of Endovascular Oncology | 2020-04-18 |
| NCT04197076 | Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIIA | https://ClinicalTrials.gov/show/NCT04197076 | Recruiting | Shanghai Chest Hospital | 2021-05-01 |
| NCT04189679 | Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma | https://ClinicalTrials.gov/show/NCT04189679 | Recruiting | University Hospital, Grenoble | 2021-11-30 |
| NCT04187768 | Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT04187768 | Recruiting | Indiana University | 2020-12-31 |
| NCT04179890 | The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib | https://ClinicalTrials.gov/show/NCT04179890 | Active, not recruiting | Boehringer Ingelheim | 2020-07-17 |
| NCT04164186 | Fully Automated Pipeline for the Detection and Segmentation of Non-Small Cell Lung Cancer (NSCLC) on CT Images | https://ClinicalTrials.gov/show/NCT04164186 | Active, not recruiting | Maastricht University | 2019-11-07 |
| NCT04154163 | Appropriate Dosing to Optimise Personalised Cancer Treatments | https://ClinicalTrials.gov/show/NCT04154163 | Recruiting | University of Dundee | 2020-07-30 |
| NCT04151940 | PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT04151940 | Recruiting | University of Washington | 2021-06-01 |
| NCT04145232 | AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient’s Response to Immunotherapies. | https://ClinicalTrials.gov/show/NCT04145232 | Recruiting | Ardigen | 2020-06-30 |
| NCT04136470 | BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics | https://ClinicalTrials.gov/show/NCT04136470 | Recruiting | Ardigen | 2020-09-30 |
| NCT04137718 | Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation | https://ClinicalTrials.gov/show/NCT04137718 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 2022-10-20 |
| NCT04116918 | Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC | https://ClinicalTrials.gov/show/NCT04116918 | Recruiting | Shanghai Changzheng Hospital | 2021-09-30 |
| NCT04087473 | Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC | https://ClinicalTrials.gov/show/NCT04087473 | Recruiting | National Cancer Centre, Singapore | 2022-06-30 |
| NCT04092465 | Outcomes of Surgical Resection After Induction Treatment in Non-Small Cell Lung Cancer (SRaIT) | https://ClinicalTrials.gov/show/NCT04092465 | Completed | AHEPA University Hospital | 2019-08-31 |
| NCT04076228 | Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients | https://ClinicalTrials.gov/show/NCT04076228 | Recruiting | Kiang Wu Hospital | 2020-01-01 |
| NCT04069663 | Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study | https://ClinicalTrials.gov/show/NCT04069663 | Completed | University Hospital, Grenoble | 2019-05-15 |
| NCT04041297 | Evaluation of NSCLC Patients’ Oxygen Uptake On-kinetics at Cycle-ergometer During Prehabilitation | https://ClinicalTrials.gov/show/NCT04041297 | Recruiting | ADIR Association | 2021-05-31 |
| NCT04037150 | Circulating DNA in Surgically Treated NSCLC | https://ClinicalTrials.gov/show/NCT04037150 | Recruiting | Helsinki University Central Hospital | 2020-12-31 |
| NCT03989050 | Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors | https://ClinicalTrials.gov/show/NCT03989050 | Recruiting | University of Cologne | 2020-08-31 |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | https://ClinicalTrials.gov/show/NCT03987555 | Recruiting | Wake Forest University Health Sciences | 2021-03-31 |
| NCT03958565 | Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations. | https://ClinicalTrials.gov/show/NCT03958565 | Recruiting | University of Colorado, Denver | 2022-03-05 |
| NCT03951233 | K-RAS and EGFR in Lung Cancer | https://ClinicalTrials.gov/show/NCT03951233 | Completed | Hellenic Cooperative Oncology Group | 2012-12-31 |
| NCT03951012 | Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy | https://ClinicalTrials.gov/show/NCT03951012 | Recruiting | University of Iowa | 2021-04-30 |
| NCT03940846 | CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology | https://ClinicalTrials.gov/show/NCT03940846 | Active, not recruiting | Maastricht University | 2020-10-31 |
| NCT03918304 | Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS | https://ClinicalTrials.gov/show/NCT03918304 | Recruiting | AstraZeneca | 2024-06-30 |
| NCT03911219 | Study to Evaluate the Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) Under 1st-line Treatment With Atezolizumab and Platinum-based Chemotherapy | https://ClinicalTrials.gov/show/NCT03911219 | Recruiting | iOMEDICO AG | 2024-06-30 |
| NCT03892096 | Development and Validation of a qPCR Cell Free DNA Assay as a Potential Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer | https://ClinicalTrials.gov/show/NCT03892096 | Active, not recruiting | Cadex Genomics | 2020-11-01 |
| NCT03877250 | Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies | https://ClinicalTrials.gov/show/NCT03877250 | Recruiting | Memorial Sloan Kettering Cancer Center | 2021-03-31 |
| NCT03844464 | Safety and Efficacy of Lorbrena | https://ClinicalTrials.gov/show/NCT03844464 | Recruiting | Pfizer | 2023-08-11 |
| NCT03836469 | Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil | https://ClinicalTrials.gov/show/NCT03836469 | Recruiting | Latin American Cooperative Oncology Group | 2020-06-03 |
| NCT03833934 | Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance | https://ClinicalTrials.gov/show/NCT03833934 | Recruiting | Addario Lung Cancer Medical Institute | 2020-08-23 |
| NCT03804554 | A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab | https://ClinicalTrials.gov/show/NCT03804554 | Active, not recruiting | Bristol-Myers Squibb | 2019-06-30 |
| NCT03791034 | Cell Free DNA for the Diagnosis and Treatment in Early NSCLC | https://ClinicalTrials.gov/show/NCT03791034 | Recruiting | Samsung Medical Center | 2020-12-31 |
| NCT03790397 | Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive | https://ClinicalTrials.gov/show/NCT03790397 | Completed | Fundación GECP | 2019-07-15 |
| NCT03764917 | NGS Combined With RNAseq on Tumor Immune Escape in NSCLC | https://ClinicalTrials.gov/show/NCT03764917 | Active, not recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 2020-12-31 |
| NCT03761901 | Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium | https://ClinicalTrials.gov/show/NCT03761901 | Completed | AstraZeneca | 2019-06-19 |
| NCT03746262 | Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03746262 | Completed | Wake Forest University Health Sciences | 2018-08-10 |
| NCT03740503 | Genomic Investigation of Unusual Responders | https://ClinicalTrials.gov/show/NCT03740503 | Active, not recruiting | University Health Network, Toronto | 2020-11-30 |
| NCT03741647 | Sleep Apnea and Lung Cancer | https://ClinicalTrials.gov/show/NCT03741647 | Active, not recruiting | Zagazig University | 2020-11-30 |
| NCT03721289 | Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients | https://ClinicalTrials.gov/show/NCT03721289 | Completed | AstraZeneca | 2019-03-09 |
| NCT03710629 | A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes | https://ClinicalTrials.gov/show/NCT03710629 | Recruiting | The First Affiliated Hospital of Guangzhou Medical University | 2022-12-01 |
| NCT03705806 | Palliative Thoracic ImmunoRT | https://ClinicalTrials.gov/show/NCT03705806 | Recruiting | University Health Network, Toronto | 2020-09-15 |
| NCT03692442 | Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform | https://ClinicalTrials.gov/show/NCT03692442 | Recruiting | Guangzhou Institute of Respiratory Disease | 2019-01-31 |
| NCT03679936 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03679936 | Recruiting | Fifth Affiliated Hospital, Sun Yat-Sen University | 2020-12-31 |
| NCT03689439 | Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? | https://ClinicalTrials.gov/show/NCT03689439 | Recruiting | Fudan University | 2021-11-01 |
| NCT03658460 | Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers | https://ClinicalTrials.gov/show/NCT03658460 | Recruiting | Aalborg University Hospital | 2019-10-01 |
| NCT03647592 | Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03647592 | Recruiting | Hunan Province Tumor Hospital | 2021-08-31 |
| NCT03647111 | Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03647111 | Recruiting | Hunan Province Tumor Hospital | 2020-12-31 |
| NCT03647098 | Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03647098 | Enrolling by invitation | Hunan Province Tumor Hospital | 2020-12-31 |
| NCT03645330 | A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL) | https://ClinicalTrials.gov/show/NCT03645330 | Active, not recruiting | Chugai Pharmaceutical | 2021-06-15 |
| NCT03646994 | Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03646994 | Recruiting | Hunan Province Tumor Hospital | 2020-12-31 |
| NCT03616522 | A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03616522 | Completed | Abramson Cancer Center of the University of Pennsylvania | 2019-02-18 |
| NCT03609918 | Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing | https://ClinicalTrials.gov/show/NCT03609918 | Completed | Tianjin Medical University Cancer Institute and Hospital | 2017-09-27 |
| NCT03576937 | Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study | https://ClinicalTrials.gov/show/NCT03576937 | Recruiting | University Health Network, Toronto | 2020-07-31 |
| NCT03562819 | Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer). | https://ClinicalTrials.gov/show/NCT03562819 | Completed | AstraZeneca | 2019-06-07 |
| NCT03512847 | Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03512847 | Recruiting | Zealand University Hospital | 2021-01-31 |
| NCT03504098 | Folate One-carbon Malnutrition as the Metabostemness Risk Factor of Malignancy Tumor Development of NSCLC Patients | https://ClinicalTrials.gov/show/NCT03504098 | Recruiting | National Taiwan University Hospital | 2020-07-31 |
| NCT03499678 | Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA | https://ClinicalTrials.gov/show/NCT03499678 | Recruiting | HKGepitherapeutics | 2020-12-01 |
| NCT03492801 | Collection of Blood Samples in Patients With Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03492801 | Recruiting | University of Southern California | 2020-12-11 |
| NCT03485326 | A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients | https://ClinicalTrials.gov/show/NCT03485326 | Recruiting | AstraZeneca | 2021-06-30 |
| NCT03465241 | ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS | https://ClinicalTrials.gov/show/NCT03465241 | Recruiting | Sun Yat-sen University | 2021-12-31 |
| NCT03457220 | An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03457220 | Completed | AstraZeneca | 2019-12-31 |
| NCT03454685 | The Role of Microbiota on the Development of Lung Cancer | https://ClinicalTrials.gov/show/NCT03454685 | Recruiting | Wuhan Union Hospital, China | 2020-01-30 |
| NCT03451526 | A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03451526 | Completed | Tang-Du Hospital | 2017-12-01 |
| NCT03427567 | A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03427567 | Completed | Tongji Hospital | 2017-12-01 |
| NCT03429673 | A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients | https://ClinicalTrials.gov/show/NCT03429673 | Completed | China-Japan Friendship Hospital | 2017-12-01 |
| NCT03429192 | A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03429192 | Completed | Tianjin Chest Hospital | 2018-03-30 |
| NCT03413956 | An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03413956 | Completed | Jiangsu Cancer Institute & Hospital | 2018-03-30 |
| NCT01261585 | Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT | https://ClinicalTrials.gov/show/NCT01261585 | Completed | Centre Henri Becquerel | 2009-11-30 |
| NCT01260038 | Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium. | https://ClinicalTrials.gov/show/NCT01260038 | Completed | University Hospital, Antwerp | 2011-09-30 |
| NCT01255150 | Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01255150 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT03872362 | Radiomics Multifactorial Biomarker for Pulmonary Nodules | https://ClinicalTrials.gov/show/NCT03872362 | Completed | Maastricht University | 2019-01-11 |
| NCT01194050 | An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01194050 | Completed | Hoffmann-La Roche | 2013-07-31 |
| NCT01167972 | Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma | https://ClinicalTrials.gov/show/NCT01167972 | Completed | AstraZeneca | 2012-09-30 |
| NCT01153399 | A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer). | https://ClinicalTrials.gov/show/NCT01153399 | Completed | AstraZeneca | 2014-12-31 |
| NCT01146366 | Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT01146366 | Completed | Washington University School of Medicine | 2014-10-31 |
| NCT01139944 | Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01139944 | Completed | Alliance for Clinical Trials in Oncology | 2014-01-31 |
| NCT01139619 | A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients | https://ClinicalTrials.gov/show/NCT01139619 | Completed | AstraZeneca | 2013-01-31 |
| NCT01124669 | Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate | https://ClinicalTrials.gov/show/NCT01124669 | Completed | Eastern Cooperative Oncology Group | 2010-07-13 |
| NCT01112631 | Prospective Study of Quality of Life in Non-small Cell Lung Cancer (NSCLC) Patients Treated With/Without Postoperative Radiotherapy | https://ClinicalTrials.gov/show/NCT01112631 | Completed | Maria Sklodowska-Curie Institute - Oncology Center | 2007-09-30 |
| NCT01103089 | Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP) | https://ClinicalTrials.gov/show/NCT01103089 | Completed | AstraZeneca | 2010-12-31 |
| NCT01081496 | Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT01081496 | Completed | AstraZeneca | 2010-08-31 |
| NCT01069835 | Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN) | https://ClinicalTrials.gov/show/NCT01069835 | Completed | AstraZeneca | 2011-03-31 |
| NCT01067794 | Chemotherapy in Treating Patients With Lung Cancer | https://ClinicalTrials.gov/show/NCT01067794 | Completed | Eli Lilly and Company | 2012-07-31 |
| NCT01065415 | Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT01065415 | Completed | Samsung Medical Center | NA |
| NCT01026467 | Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT01026467 | Completed | Wake Forest University Health Sciences | 2014-05-31 |
| NCT01023828 | K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications | https://ClinicalTrials.gov/show/NCT01023828 | Completed | National Institute of CancerologÃa | 2010-01-31 |
| NCT00997230 | Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m | https://ClinicalTrials.gov/show/NCT00997230 | Completed | AstraZeneca | 2012-10-31 |
| NCT00973427 | DNA Chip Based Prognosis of Lung Cancer | https://ClinicalTrials.gov/show/NCT00973427 | Completed | Medical Prognosis Institute A/S | 2014-09-30 |
| NCT00960271 | Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT00960271 | Completed | University Hospital, Rouen | 2010-12-31 |
| NCT00956280 | Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT00956280 | Completed | AstraZeneca | 2010-04-30 |
| NCT00923884 | Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer | https://ClinicalTrials.gov/show/NCT00923884 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT00922025 | Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients | https://ClinicalTrials.gov/show/NCT00922025 | Completed | AstraZeneca | 2010-12-31 |
| NCT00897234 | Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers | https://ClinicalTrials.gov/show/NCT00897234 | Completed | University of Minnesota | 2010-08-31 |
| NCT00899756 | Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT00899756 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-12-31 |
| NCT00890903 | Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) | https://ClinicalTrials.gov/show/NCT00890903 | Completed | Pierre Fabre Pharma GmbH | 2012-04-30 |
| NCT00862030 | CT-Based Versus Conventional Simulation for Palliative Radiotherapy of Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT00862030 | Completed | AHS Cancer Control Alberta | 2011-01-31 |
| NCT03798535 | First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy | https://ClinicalTrials.gov/show/NCT03798535 | Recruiting | AstraZeneca | 2023-12-20 |
| NCT03724604 | NSE/Alb as a Prognostic Biomarker for Lung Cancer | https://ClinicalTrials.gov/show/NCT03724604 | Recruiting | First Affiliated Hospital Xi’an Jiaotong University | 2019-06-30 |
| NCT03724500 | Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03724500 | Recruiting | Chang Gung Memorial Hospital | 2020-12-31 |
| NCT01106781 | A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology | https://ClinicalTrials.gov/show/NCT01106781 | Completed | AstraZeneca | 2014-01-31 |
| NCT00831909 | Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN | https://ClinicalTrials.gov/show/NCT00831909 | Completed | AstraZeneca | 2010-07-31 |
| NCT00831454 | Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection | https://ClinicalTrials.gov/show/NCT00831454 | Completed | Istituto Clinico Humanitas | 2011-12-31 |
| NCT04294108 | Why in Hospital After VATS Lobectomy | https://ClinicalTrials.gov/show/NCT04294108 | Recruiting | Rigshospitalet, Denmark | 2020-09-16 |
| NCT02751879 | Real World Data on Gi(l)Otrif® Dose Adjustment | https://ClinicalTrials.gov/show/NCT02751879 | Completed | Boehringer Ingelheim | 2017-09-30 |
| NCT01522833 | Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer | https://ClinicalTrials.gov/show/NCT01522833 | Completed | SCRI Development Innovations, LLC | 2015-02-28 |
| NCT01505400 | Integrated Molecular Profiling in Advanced Cancers Trial | https://ClinicalTrials.gov/show/NCT01505400 | Active, not recruiting | University Health Network, Toronto | 2021-01-31 |
| NCT03916367 | CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer | https://ClinicalTrials.gov/show/NCT03916367 | Completed | Peking University Third Hospital | 2018-12-15 |
| NCT03870464 | LIFE - Lung Cancer, Immunotherapy, Frailty, Effect | https://ClinicalTrials.gov/show/NCT03870464 | Recruiting | University of Southern Denmark | 2021-09-30 |
| NCT03838588 | The Tracking Molecular Evolution for NSCLC (T-MENC) Study | https://ClinicalTrials.gov/show/NCT03838588 | Recruiting | Geneplus-Beijing Co. Ltd. | 2021-12-31 |
| NCT03727477 | Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib | https://ClinicalTrials.gov/show/NCT03727477 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 2020-06-30 |
| NCT02689050 | Optical Biopsy for Thoracic Lymph Nodes. | https://ClinicalTrials.gov/show/NCT02689050 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2017-03-22 |
| NCT02440854 | Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings | https://ClinicalTrials.gov/show/NCT02440854 | Active, not recruiting | Boehringer Ingelheim | 2021-03-22 |
| NCT04266691 | Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT04266691 | Completed | Zhejiang Cancer Hospital | 2015-12-31 |
| NCT04023812 | Stage III NSCLC RWE in Chinese Patients | https://ClinicalTrials.gov/show/NCT04023812 | Recruiting | AstraZeneca | 2022-05-30 |
| NCT03939481 | Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer | https://ClinicalTrials.gov/show/NCT03939481 | Recruiting | Southwest Oncology Group | 2025-02-28 |
| NCT03725475 | A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients | https://ClinicalTrials.gov/show/NCT03725475 | Completed | AstraZeneca | 2019-09-30 |
| NCT03613467 | Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients | https://ClinicalTrials.gov/show/NCT03613467 | Completed | Tang-Du Hospital | 2018-07-04 |
| NCT03559647 | The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy | https://ClinicalTrials.gov/show/NCT03559647 | Active, not recruiting | Hoffmann-La Roche | 2023-05-12 |
| NCT00763607 | Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT00763607 | Completed | Istituto Clinico Humanitas | 2008-02-29 |
| NCT00759382 | Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study. | https://ClinicalTrials.gov/show/NCT00759382 | Active, not recruiting | European Lung Cancer Working Party | 2021-01-31 |
| NCT00717847 | A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib | https://ClinicalTrials.gov/show/NCT00717847 | Completed | National University Hospital, Singapore | 2013-04-30 |
| NCT00717002 | Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study | https://ClinicalTrials.gov/show/NCT00717002 | Completed | National University Hospital, Singapore | 2013-04-30 |
| NCT00671242 | Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake | https://ClinicalTrials.gov/show/NCT00671242 | Completed | Gunma University | NA |
| NCT00641238 | Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA) | https://ClinicalTrials.gov/show/NCT00641238 | Completed | State University of New York - Upstate Medical University | 2011-02-28 |
| NCT00602433 | Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib | https://ClinicalTrials.gov/show/NCT00602433 | Completed | Northwestern University | 2009-08-31 |
| NCT00603057 | Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer | https://ClinicalTrials.gov/show/NCT00603057 | Completed | University of Michigan Rogel Cancer Center | 2013-09-30 |
| NCT00579683 | Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT00579683 | Completed | Memorial Sloan Kettering Cancer Center | 2016-02-29 |
| NCT00572325 | Concurrent Chemo-radiation Form NSCLC to a Individualized MLD | https://ClinicalTrials.gov/show/NCT00572325 | Completed | Maastricht Radiation Oncology | NA |
| NCT00573040 | Radiotherapy for NSCLC to a Individualized MLD | https://ClinicalTrials.gov/show/NCT00573040 | Completed | Maastricht Radiation Oncology | NA |
| NCT00501319 | Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery | https://ClinicalTrials.gov/show/NCT00501319 | Completed | M.D. Anderson Cancer Center | 2011-10-31 |
| NCT00464282 | Fluorine-18-α–Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer | https://ClinicalTrials.gov/show/NCT00464282 | Completed | Gunma University | NA |
| NCT00450281 | S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT00450281 | Completed | Southwest Oncology Group | 2012-07-31 |
| NCT00419042 | Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT00419042 | Completed | Groupe Francais De Pneumo-Cancerologie | 2006-09-30 |
| NCT00418704 | Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT00418704 | Completed | Groupe Francais De Pneumo-Cancerologie | 2006-06-30 |
| NCT00409968 | BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT00409968 | Completed | M.D. Anderson Cancer Center | 2019-10-31 |
| NCT00388206 | A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) | https://ClinicalTrials.gov/show/NCT00388206 | Completed | Genentech, Inc. | 2012-03-31 |
| NCT00351598 | Lung Tumour Volume Database | https://ClinicalTrials.gov/show/NCT00351598 | Completed | Trans-Tasman Radiation Oncology Group (TROG) | 2009-02-28 |
| NCT00352391 | Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients | https://ClinicalTrials.gov/show/NCT00352391 | Completed | M.D. Anderson Cancer Center | 2016-01-31 |
| NCT00341380 | Prevention of Tumor Spread Due to Lung Cancer Surgery | https://ClinicalTrials.gov/show/NCT00341380 | Completed | National Institutes of Health Clinical Center (CC) | 2007-04-13 |
| NCT00280202 | Detection of Genetic Markers of Lung Cancer | https://ClinicalTrials.gov/show/NCT00280202 | Recruiting | University of Pittsburgh | 2050-12-31 |
| NCT00263731 | Metabolomic Analysis of Lung Cancer | https://ClinicalTrials.gov/show/NCT00263731 | Recruiting | University of Louisville | 2025-12-31 |
| NCT00252759 | Iressa Case Control Study in Japan | https://ClinicalTrials.gov/show/NCT00252759 | Completed | AstraZeneca | NA |
| NCT00222404 | Pharmacogenomic Study Realized on “Non-small Cell Lung Carcinoma” | https://ClinicalTrials.gov/show/NCT00222404 | Completed | University Hospital, Grenoble | NA |
| NCT00213733 | Molecular Assessment of Lymph Nodes in Patients With Resected (Stage I to IIIA) Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT00213733 | Completed | University Hospital, Strasbourg, France | NA |
| NCT00094822 | Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT00094822 | Completed | Amgen | 2005-12-31 |
| NCT00077324 | Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions | https://ClinicalTrials.gov/show/NCT00077324 | Completed | Alliance for Clinical Trials in Oncology | 2011-11-30 |
| NCT01936571 | Usefulness of Blood Biomarkers for Overall Survival in NSCLC | https://ClinicalTrials.gov/show/NCT01936571 | Completed | Maastricht Radiation Oncology | 2014-02-28 |
| NCT00071344 | Analysis of Brain Metastasis in Patients With Lung Cancer | https://ClinicalTrials.gov/show/NCT00071344 | Completed | National Institutes of Health Clinical Center (CC) | NA |
| NCT00818402 | Non-small Cell Lung Cancer and Quality of Life | https://ClinicalTrials.gov/show/NCT00818402 | Completed | University of Turku | 2012-02-29 |
#If less then 500 registries
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT03824977 | Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery | https://ClinicalTrials.gov/show/NCT03824977 | Recruiting | University Hospital, Rouen | 2018-11-21 |
| NCT03334864 | Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG) | https://ClinicalTrials.gov/show/NCT03334864 | Recruiting | Peking Union Medical College Hospital | 2023-12-31 |
| NCT03299478 | Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03299478 | Recruiting | University Hospital of North Norway | 2024-11-30 |
| NCT03235765 | Cancer Panel From Blood of Lung Cancer Patients | https://ClinicalTrials.gov/show/NCT03235765 | Active, not recruiting | Seoul National University Hospital | 2019-03-10 |
| NCT03125603 | Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung Cancer | https://ClinicalTrials.gov/show/NCT03125603 | Completed | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2018-08-01 |
| NCT03066297 | Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03066297 | Recruiting | Samsung Medical Center | 2027-02-15 |
| NCT02991924 | Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer | https://ClinicalTrials.gov/show/NCT02991924 | Active, not recruiting | National Cancer Center, Korea | 2019-12-31 |
| NCT02965391 | Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients | https://ClinicalTrials.gov/show/NCT02965391 | Completed | Peking University People’s Hospital | 2017-09-30 |
| NCT02778854 | Liquid Biopsy for Detection of Driver Mutation in NSCLC | https://ClinicalTrials.gov/show/NCT02778854 | Recruiting | Chinese PLA General Hospital | 2018-12-31 |
| NCT02777658 | PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC | https://ClinicalTrials.gov/show/NCT02777658 | Completed | AstraZeneca | 2020-05-31 |
| NCT02730897 | Multicentric Analysis of Predictors of N1 Upstaging After Resection of cStage-I NSCLC | https://ClinicalTrials.gov/show/NCT02730897 | Completed | University Hospital, Gasthuisberg | 2016-10-31 |
| NCT02622581 | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients | https://ClinicalTrials.gov/show/NCT02622581 | Recruiting | AIO-Studien-gGmbH | 2023-09-30 |
| NCT02113852 | Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients | https://ClinicalTrials.gov/show/NCT02113852 | Completed | Guangdong Association of Clinical Trials | 2016-05-31 |
| NCT01963351 | Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC | https://ClinicalTrials.gov/show/NCT01963351 | Completed | University of Athens | 2014-01-31 |
| NCT01951755 | Phase IV Study of Tarceva in Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer (NSCLC) | https://ClinicalTrials.gov/show/NCT01951755 | Completed | University of Athens | 2014-01-31 |
| NCT01838577 | Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study | https://ClinicalTrials.gov/show/NCT01838577 | Active, not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 2018-10-31 |
| NCT01808677 | Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy | https://ClinicalTrials.gov/show/NCT01808677 | Completed | M.D. Anderson Cancer Center | 2016-08-31 |
| NCT04266483 | Cancer Genome Atlas of China:Lung Cancer | https://ClinicalTrials.gov/show/NCT04266483 | Recruiting | Xuanwu Hospital, Beijing | 2022-11-08 |
| NCT04216121 | LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib | https://ClinicalTrials.gov/show/NCT04216121 | Recruiting | Universitaire Ziekenhuizen Leuven | 2023-02-28 |
| NCT04153097 | Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC | https://ClinicalTrials.gov/show/NCT04153097 | Recruiting | First Affiliated Hospital of Zhejiang University | 2020-11-30 |
| NCT04137588 | Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT04137588 | Recruiting | Beijing Cancer Hospital | 2022-03-01 |
| NCT03995875 | Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC | https://ClinicalTrials.gov/show/NCT03995875 | Recruiting | AstraZeneca | 2023-12-31 |
| NCT03791151 | Pharmacogenetics in Non Small Cell Lung Cancer | https://ClinicalTrials.gov/show/NCT03791151 | Recruiting | Ain Shams University | 2019-11-30 |
| NCT03643484 | IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy | https://ClinicalTrials.gov/show/NCT03643484 | Active, not recruiting | AstraZeneca | 2021-06-30 |
| NCT03605602 | A Real World Study Based on NGS (TRUMPRWS) | https://ClinicalTrials.gov/show/NCT03605602 | Recruiting | Guangdong Association of Clinical Trials | 2022-12-30 |
| NCT03305380 | Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth | https://ClinicalTrials.gov/show/NCT03305380 | Recruiting | Maastricht Radiation Oncology | 2020-12-01 |